HealthCare Middle East & Africa - Issue 13

MIDDLE EAST & AFRICA

FEATURE:

AGC Tenwek Hospital opens new cardiothoracic centre in Kenya

COMPANY FEATURE: DAWA LIFE SCIENCES

Three decades of transforming healthcare in East and Southern Africa

ASSOCIATION FOCUS: RUPHA

The voice for medically underserved populations in Kenya

TOPICAL FOCUS: IVF TREATMENT

A Miracle in a Dish: The Power of IVF and the Future of Family

STARTUP FEATURE: BENACARE

Healthcare at the doorstep: How BenaCare’s “hospital at home” is redefining care for Kenya’s chronically ill

COMPANY FEATURE: AGC TENWEK HOSPITAL

A legacy of compassionate care and advanced medical services

DISEASE FOCUS: SICKLE CELL ANAEMIA

Breaking the Chains: Bridging the Gap in Sickle Cell Disease Management in Africa

Year 3 | Issue No. 13 |OCT-DEC 2024

FOUNDER & PUBLISHER

Francis Juma

SENIOR EDITOR

Alphonse Okoth

ASSISTANT LEAD EDITOR

Jackie Muinde

EDITOR

Vincent Moranga

BUSINESS DEVELOPMENT DIRECTOR

Virginia Nyoro

BUSINESS DEVELOPMENT ASSOCIATE

Elly Okutoyi

HEAD OF DESIGN

OUR MAGAZINES

MIDDLE EAST & AFRICA www.hotelhospitalitymea.com

Clare Ngode

DESIGN

Monica Wachio

ACCOUNTS

Jonah Sambai

PUBLISHED BY: FW Africa

P.O. Box 1874-00621, Nairobi Kenya

Tel: +254 725 34 39 32

Email: info@fwafrica.net

Company Website: www.fwafrica.net

HealthCare Africa (ISSN 2307-3535) is published 4 times a year by FW Africa. Reproduction of the whole or any part of the contents without written permission from the editor is prohibited. All information is published in good faith. While care is taken to prevent inaccuracies, the publishers accept no liability for any errors or omissions or for the consequences of any action taken on the basis of information published.

We publish some of the most influential magazines and websites in Africa & the Middle East regions. Please visit the websites below for more information about our publications

www.foodbusinessafrica.com

www.animalfeedmea.com

www.healthcaremea.com

Key reminders from diabetes awareness month

Every November, Diabetes Awareness Month invites us to pause and reflect on a condition that touches millions of lives around the world. It’s more than just a month on the calendar—it’s a call to action, a time to learn, and an opportunity to show support for those living with diabetes. It reminds us of the challenges and triumphs of managing this chronic condition, while inspiring hope for a healthier, brighter future.

The statistics are sobering. According to the World Health Organization, about 830 million people globally are living with diabetes, most in low- and middle-income countries. Even more concerning, more than half of these individuals lack access to proper treatment. For many, this means facing preventable complications or even premature death. The numbers continue to rise, painting a picture of urgency that cannot be ignored.

But this month is about more than just numbers. It’s about people—our friends, family, colleagues, and neighbors. It’s about understanding their stories, their struggles, and their strength. Diabetes Awareness Month encourages us to educate ourselves, to advocate for better care and resources, and to imagine a future where diabetes is no longer a burden on so many lives.

While reflecting on these realities, let me warmly welcome you to the 12th issue of Healthcare Middle East & Africa. This edition is packed with stories that shine a light on the resilience and innovation shaping healthcare in our region.

One story that stands out is that of Dawa Life Science, a Kenyan pharmaceutical company that has spent over three decades delivering life-saving solutions across East and Southern Africa. Their journey is a testament to the power of perseverance and the impact of localized healthcare solutions.

Another inspiring feature focuses on AGC Tenwek Hospital in Bomet County, Kenya. This

rural hospital has accomplished something extraordinary—a US$35 million Cardiothoracic Center that provides world-class heart care and surgeries. It’s a beacon of hope for a region where such facilities are scarce.

We also bring you the heartfelt mission of Bena Care, a social enterprise that offers affordable, compassionate home-based nursing and therapy services. This aligns beautifully with our piece on the Rural-Urban Private Hospital Association (RUPHA), which helps uninsured patients access essential medical care.

Beyond these stories, we explore infertility, sickle cell disease, and Kenya’s growing wellness and spa industry. Plus, you’ll find the latest news on innovations, suppliers, and regulations from Africa and beyond.

Thank you for joining us. May this edition inspire you as much as it inspired us to create it. Enjoy the read!

Alphonse Okoth Senior Editor HCMEA

REGULATORY

Kenya government orders inspection of cosmetic Clinics after death of patient

KENYA — The Kenyan State Department of Public Health & Professional Standards has initiated a comprehensive review of facilities offering invasive cosmetic procedures.

This move comes in response to the tragic death of Ms. Lucy Wambui during a cosmetic surgery at Omnicare, also known as Body by Design.

The Ministry of Health, led by Principal Secretary Mary Muthoni Muriuki, has emphasized the urgency of ensuring safety and quality standards within the cosmetic surgery industry.

The Kenya Health Professions Oversight Authority, along with other regulatory bodies, will conduct inspections to verify compliance with safety protocols.

126 Beauty and Medical Spas and 34 Plastic Surgery Centers across Nairobi, Nakuru, Eldoret, and Mombasa will be scrutinised. Authorities aim to ensure these facilities adhere to ethical practices and employ qualified professionals.

During these inspections, any facility that violates safety standards will face severe consequences, including closure and legal action.

The Ministry’s actions signal a strong commitment to holding service providers accountable for upholding safety standards and ensuring that cosmetic procedures are performed safely and professionally to protect the public.

Additionally, the Ministry has reminded healthcare providers to

strictly follow regulations, prioritize patient safety, and maintain high ethical standards.

The Ministry also advised public caution, urging individuals to seek services only from licensed and certified professionals and facilities. This is essential to minimize the risks associated with unregulated or unsafe practices.

The State Department has also pledged to continue its efforts in monitoring healthcare facilities across the nation.

Regular regulation enforcement and adherence to standards will be a top priority to safeguard the health and well-being of Kenyans.

Sanofi partners with Sudair Pharma to establish insulin production facility in Saudi Arabia PARTNERSHIP

SAUDI ARABIA — A significant offtake agreement has been signed at the Global Health Exhibition in Riyadh to establish a state-of-the-art manufacturing facility that produces Sanofi’s SoloStar insulin pens and advanced insulin products.

Under the agreement, French drugmaker Sanofi will collaborate with Saudi’s Sudair Pharma Company (SPC) to establish a cutting-edge

manufacturing facility in the Kingdom of Saudi Arabia.

The new facility will encompass the entire production process, including delivery, device assembly, and packaging, reinforcing the commitment to reducing the dependency on imported medicines.

This agreement was signed under the patronage of notable officials, including His Excellency Mr. Fahad bin Abdulrahman Al-Jalajel, the Minister of Health; His Excellency Mr. Bandar bin Ibrahim Al-Khorayef, the Minister of Industry and Mineral Resources; and His Excellency Engineer Khaled bin Abdulaziz Al-Faleh, the Minister of Investment.

This partnership is expected to significantly enhance access to highquality insulin for individuals living with diabetes and support the Kingdom’s ambitions to become a regional hub for

manufacturing biological medicines, aligning with Vision 2030.

As part of this strategic alliance, Sanofi will transfer its technical expertise and global knowledge in biological technologies to Sudair Pharma, facilitating full production within Saudi Arabia.

This initiative aims to boost local content and promote the localization of essential biopharmaceutical industries, enhancing economic diversification and elevating the Kingdom’s standing in the life sciences sector.

Diabetes continues to be a pressing global health issue, making it critical to ensure a continuous and reliable supply of high-quality insulin to meet the Kingdom’s needs.

Through this partnership, Sanofi and Sudair Pharma intend to effectively address this gap, thereby improving access to care for those with diabetes.

HOSPITALS

Angola inaugurates Cuanza Norte General Hospital

ANGOLA — President João Gonçalves Lourenço has opened Cuanza Norte General Hospital, Mitrelli’s third healthcare facility built in partnership with the Angolan government in a year.

This inauguration coincides with the beginning of Angola’s 50th year of independence, with the new hospital being a vital part of Angola’s efforts to provide comprehensive healthcare access to its citizens.

Other notable figures attended the event, including the Governor of Cuanza Norte, João Diogo Gaspar, the Minister of Health, Silvia Lutucuta, and other government officials, religious leaders, and traditional authorities.

With a capacity of 200 beds and a floor area of 15,000 square meters, the hospital will serve not only the 500,000 residents of Cuanza Norte but also thousands more from neighbouring

INVESTMENTS

ICD

invests

provinces.

The hospital features a range of specialized services, including oncology, surgery, rehabilitation, paediatrics, and maternity care. It also includes advanced adult and neonatal intensive care units (ICUs).

The facility, equipped with state-ofthe-art imaging diagnostics, a clinical analysis laboratory, and a hospital waste processing unit, is designed to deliver high-quality care while maintaining environmental sustainability.

Alongside the Cuanza Norte General Hospital, two other Mitrelli-built hospitals — the General Hospital in Cuanza Sul (October 2024) and Bengo General Hospital (November 2023) — are already operational.

Together, these three hospitals serve over 3 million residents and offer 600 beds across more than 100,000 square

meters of healthcare infrastructure. The expansion of this healthcare network has also created nearly 4,000 jobs, significantly contributing to local economic growth.

WITH A CAPACITY OF 200 BEDS AND A FLOOR AREA OF 15,000 SQUARE METERS, THE HOSPITAL WILL SERVE THE 500,000 RESIDENTS OF CUANZA NORTE.

US$42M in Kokshetau Hospital project in Kazakhstan

KAZAKHSTAN – The Islamic Corporation for the Development of the Private Sector (ICD) has entered a EUR 40 million (US$42.13 million) agreement to co-finance the Kokshetau Hospital Project in Kazakhstan.

This project represents ICD’s first venture into a Public-Private Partnership (PPP) in Kazakhstan and the first PPP in the country’s healthcare sector.

It will also be the first of its kind in Central Asia, involving the greenfield

development of a state-of-the-art 110,000-square-meter healthcare facility.

The new hospital will serve over 730,000 people in the city of Kokshetau and the surrounding Akmola region.

Under the terms of the PPP agreement, a private partner will be responsible for maintaining the facility and operating a 24-hour Hospital Information Management System (HIMS).

This digital system aims to set a new standard for healthcare in Kazakhstan, enhancing the country’s medical infrastructure and services.

Turar Healthcare, a non-profit, stateowned organization, will oversee the hospital’s medical operations and ensure quality healthcare services for the local population.

The total cost of the project, which will be co-financed by several

major institutions, including the European Bank for Reconstruction and Development (EBRD), the Asian Infrastructure Investment Bank (AIIB), the German Investment Corporation (DEG), Proparco, the ICD, and the Development Bank of Kazakhstan (DBK), is expected to reach up to €365 million (US$383.97 million).

In addition to providing advanced medical services, the hospital will aim for high environmental standards. It is set to pursue a “Silver” rating under the Leadership in Energy and Environmental Design (LEED) greenbuilding certification, which recognizes top-tier building strategies and sustainable practices.

The hospital will also seek an EDGE certification for water and energy savings, further supporting its commitment to environmental sustainability.

DISINVESTMENTS

Pfizer explores sale of hospital drugs division amid restructuring efforts

USA — Pfizer, the American pharmaceutical giant, is exploring the possibility of selling its hospital drugs division, which specialises in antibiotics and sterile injectables for use in hospitals and clinics.

This potential sale comes as Pfizer faces mounting pressure from activist investor Starboard Value, which has urged the company to divest noncore assets and streamline its operations to enhance performance.

Starboard has been critical of Pfizer’s strategy of large acquisitions, questioning whether these deals have yielded sufficient returns on investment.

The investor has also highlighted the company’s struggles to produce groundbreaking new drugs from its research and development pipeline.

In response to these concerns, Pfizer has enlisted Goldman Sachs to assess potential buyers for the hospital

REGULATORY

drugs division, which may include pharmaceutical companies and private equity firms.

Known as Pfizer Hospital, the division was created in 2015 after Pfizer’s US$17 billion acquisition of Hospira, a leading manufacturer of injectable drugs and infusion technologies. This purchase allowed Pfizer to expand into the sterile injectables market.

Following the acquisition, Pfizer integrated Hospira’s biosimilars business, which produces cost-effective alternatives to expensive biotech drugs. However, in 2017, Pfizer sold Hospira’s hospital infusion systems business as part of its efforts to reshape its portfolio. Today, Pfizer Hospital operates as a standalone unit, primarily focusing on antibiotics and hospitaluse drugs, generating nearly US$500 million in earnings before interest, taxes, depreciation, and amortization

(EBITDA).

Reuters suggests that Pfizer might retain the hospital drugs division despite these prospects. Meanwhile, the company has divested other noncore assets to address its financial challenges. Last month, Pfizer sold its US$3.26 billion stake in Haleon, a UKbased consumer healthcare group, as part of its broader strategy to reduce its US$61.5 billion debt load by the end of 2023.

These restructuring efforts are crucial for Pfizer, as CEO Albert Bourla faces increasing scrutiny to deliver profitable innovations. The company’s ongoing reevaluation of its investments and portfolio reflects a commitment to strengthening its financial position and addressing shareholder concerns.

GSK’s Arexvy gains expanded approval for adults aged 5059 in Japan

JAPAN — GSK has announced that Japan’s Ministry of Health, Labour, and Welfare (MHLW) has approved the expansion of Arexvy, its respiratory syncytial virus (RSV) vaccine, to include individuals aged 50-59 who are at higher risk of severe RSV-related illness.

Previously, Arexvy was approved in Japan for adults aged 60 and above to prevent RSV-related disease, with the initial authorisation granted in September 2023.

The expanded approval is based on data from a global Phase III clinical trial, which included four sites in Japan.

The study demonstrated that the vaccine provided comparable immunogenicity in adults aged 50-59 at increased risk of severe RSV compared

to those aged 60 and older.

Additionally, the vaccine’s safety and tolerability in this age group were consistent with earlier findings in older adults.

RSV is a highly contagious virus that affects the lungs and respiratory system, impacting approximately 64 million people worldwide annually.

While RSV can affect people of all ages, adults with certain medical conditions, weakened immune systems, or those of advanced age are more vulnerable to complications such as pneumonia, exacerbation of chronic conditions like COPD and asthma, hospitalisation, and even death.

Globally, Arexvy has been approved for at-risk adults aged 50–59 in 35

countries, including the United States.

RSV IS A HIGHLY CONTAGIOUS VIRUS THAT AFFECTS THE LUNGS AND RESPIRATORY SYSTEM, IMPACTING

INVESTMENTS

Dis-Chem Pharmacies to launch new insurance business in 2025

SOUTH AFRICA — Dis-Chem

Pharmacies, a well-known South African pharmacy firm, has announced plans to create its own insurance company, Dis-Chem Life, in the first quarter of 2025 to expand its offerings beyond typical pharmacy retail.

Dis-Chem made headlines in August when it paid R155.9 million (US$8.84 million) for a 50% ownership in OneSpark, a financial services provider and life insurer.

While OneSpark does not hold an insurance license itself, it provides various insurance products such as funeral cover and life insurance, which Guardrisk Life Limited underwrites.

One of its key selling points is the affordability of its insurance plans. With premiums starting as low as R30 (US$1.72) per month, insurance is more

PARTNERSHIP

accessible to a broader audience.

As part of its life insurance offerings, OneSpark will provide several essential services, including life cover, disability cover, temporary income protection, and illness cover.

In its statement, Dis-Chem highlighted that OneSpark’s specialized knowledge will play a crucial role in fulfilling its vision of increasing access to quality healthcare at affordable prices.

This initiative aligns with the company’s commitment to provide comprehensive health solutions catering to South Africans’ needs.

Entering the insurance market will position Dis-Chem against established players in the industry, including Discovery, Old Mutual, Outsurance, and Momentum.

These competitors recently reported

positive results, despite the challenges posed by the newly signed Health Insurance Bill (NHI) and the Two-pot retirement system, which may lead to unpredictable claims from policyholders.

However, industry experts remain cautiously optimistic, especially following the country’s first interest rate cut in over four years last month, with expectations for another cut on the horizon.

In its recent performance report, Dis-Chem revealed that its headline earnings per share for the six months ending August 31 increased by 16.3%, while group revenue rose by 9.6%, totaling R19.6 billion (US$ 1.123 billion).

Considering these positive financial results, the company declared an interim dividend of 26.98 cents per share.

USAID boosts malaria fight in Nigeria with US$2.3M investment

NIGERIA — The U.S. Agency for International Development (USAID) has committed US$2.3 million to enhance access to essential malaria treatments in Nigeria and West Africa.

This funding will facilitate the procurement of 4.8 million doses of life-saving malaria tablets from Swiss Pharma Nigeria (Swipha), marking a pivotal partnership designed to strengthen regional healthcare capabilities.

This initiative is part of the President’s Malaria Initiative (PMI), which underscores the United States’ dedication to improving healthcare infrastructure in Nigeria.

The PMI focuses on providing critical support to vulnerable communities, ensuring that effective malaria treatments are readily available to those in need.

Nigeria has faced considerable

challenges in sourcing affordable, highquality medicines due to high production costs and the limited capacity of local pharmaceutical companies to meet international standards.

According to the World Health Organization (WHO), less than 10% of medicines produced in sub-Saharan Africa comply with global quality benchmarks, significantly affecting the availability of essential treatments for malaria and maternal and child health.

In response to these challenges, USAID has partnered with Swipha to achieve WHO prequalification for sulfadoxine/pyrimethamine (SP) tablets, a crucial medication for preventing malaria during pregnancy.

This certification not only positions Swipha as a leader in quality medicine production within the region but also enhances Nigeria’s ability to manufacture trusted medicines locally.

With this achievement, Swipha becomes the first pharmaceutical company in Nigeria and West Africa to obtain WHO prequalification for SP tablets, representing a crucial advancement for the local pharmaceutical sector.

NEWS UPDATES

RDB partners with Bio Usawa to bring affordable Eye Care to Africa

RWANDA — The Rwanda Development Board (RDB) has partnered with Bio Usawa Inc., a US-based healthcare company, to establish Rwanda’s first manufacturing facility to produce affordable treatments for severe eye diseases, particularly diabetic macular edema (DME).

This collaboration marks a pivotal

REGULATORY

step in enhancing healthcare access across Africa, where the prevalence of diabetes and related complications is rapidly increasing.

DME is a serious eye condition that occurs when fluid leaks from damaged blood vessels in the retina, leading to swelling and potential vision loss.

It affects approximately 7–10% of individuals with diabetes and can result in permanent blindness if left untreated.

Despite the availability of effective monoclonal antibody (mAb) treatments for DME in high-income countries, access remains severely limited in many African nations.

This new facility aims to bridge that gap by locally producing high-quality mAb biosimilars at affordable prices.

Menghis Bairu, CEO of Bio Usawa, emphasized the company’s commitment to increasing biomanufacturing capacity in Africa.

“Our long-term goal is clear: to build biomanufacturing capacity across Africa, by Africans and for Africans, ensuring that no patient is denied lifesaving therapies due to prohibitive costs,” He stated. This initiative aligns with Rwanda’s vision of becoming an East African healthcare hub.

Francis Gatare, CEO of RDB, highlighted the importance of this partnership in addressing critical healthcare challenges.

He remarked that establishing a facility for mAb biosimilars represents a major milestone for Rwanda’s healthcare sector and will significantly improve access to essential treatments for conditions like DME.

Production at the new plant is expected to commence within 18 to 24 months, paving the way for a more sustainable healthcare landscape in the region.

NAFDAC warns of counterfeit antimalarial drug in Nigeria

NIGERIA — The National Agency for Food and Drug Administration and Control (NAFDAC) has warned about a counterfeit antimalarial drug, Combiart Dispersible Tablet, circulating in Nigeria.

During routine Federal Capital Territory and Rivers State surveillance, NAFDAC officials discovered the counterfeit product, which India-based Strides Arcolab Limited manufactures.

Combiart, a combination of Artemether and Lumefantrine, is used to treat malaria, but it is not suitable for severe or complicated cases.

Laboratory tests conducted by NAFDAC revealed that the counterfeit product lacks the essential active pharmaceutical ingredients (APIs) necessary for its effectiveness.

Additionally, the product’s authenticity is further compromised by inconsistent date markings, with two

different manufacturing dates (June and February 2023) and expiry dates (May and June 2026).

The agency has confirmed that the product’s registration number is incorrect and the license has expired, making its sale illegal.

The affected counterfeit batches bear the number 7225119 and registration number A11-0299.

To address the issue, NAFDAC has directed its zonal directors and state coordinators to intensify surveillance efforts and remove any counterfeit products from the market.

The agency strongly urges the public, healthcare professionals, and consumers to exercise caution when purchasing medical products.

It is crucial to procure products only from licensed and authorized suppliers and to verify their authenticity.

Consumers who suspect they have encountered counterfeit drugs are encouraged to report them to the nearest NAFDAC office.

COMBIART, A COMBINATION OF ARTEMETHER AND LUMEFANTRINE, IS USED TO TREAT MALARIA, BUT IT IS NOT SUITABLE FOR SEVERE OR COMPLICATED CASES.

DFC, IFC, Proparco, and DEG invest US$552 M in Aspen Pharmacare

SOUTH AFRICA – A consortium of international development finance institutions, including the U.S. International Development Finance Corporation (DFC), the International Finance Corporation (IFC), Proparco, and the German Development Finance Institution (DEG), has announced a €500 million (US$552.21 million) financing package for Aspen Pharmacare

REGULATORY

Holdings Limited (Aspen).

The funding, granted to Aspen Treasury Ireland Limited, a whollyowned subsidiary of Aspen, will primarily benefit Aspen Pharma Group, Africa’s largest pharmaceutical conglomerate.

A significant portion of the proceeds will be allocated to bolster Aspen’s “Manufacturing in Africa for Africa” strategy, which aims to enhance the production and accessibility of critical medications across the continent.

The investment breakdown includes €110 million from DFC, €150 million from the IFC, and an additional €240 million in parallel loans secured by DEG and Proparco.

This financial support was announced in the presence of key executives from Aspen and the participating institutions.

The loan package will support Aspen’s local efforts to manufacture essential medicines, such as insulins and pediatric vaccines.

Additionally, it will strengthen Aspen’s distribution and promotional capabilities, ensuring wider availability of life-saving medications in SubSaharan Africa.

Beyond its immediate impact, the funding will enhance Aspen’s financial resilience, providing the necessary working capital to meet growing demand across the continent.

In a separate announcement, Aspen Group CEO Stephen Saad revealed plans to enter the GLP-1 domain in 2026.

This strategic move follows the expiration of original product patents and the acquisition of a commercial license for GLP-1-related intellectual property.

Aspen aims to commercialize these therapies and secure an exclusive worldwide supplier role for Eli Lilly’s diabetic drug, Mounjaro, in South Africa, starting in 2023.

Rwanda expands access to Assisted Reproductive Technologies

RWANDA—The Rwandan government has introduced a draft law aimed at broadening access to assisted reproductive technologies (ART), including surrogacy.

Health Minister Sabin Nsanzimana explained that this bill, introduced on November 5, builds upon the country’s 2024 Family and Personal Status law, providing specific regulations for ART services.

The bill outlines strict criteria for surrogacy. Intended parents must obtain medical confirmation of their inability to conceive or carry a pregnancy.

Surrogate mothers must be between 21 and 40 years old, have a history of healthy pregnancies, and be in good health.

The intended parent is responsible for finding a surrogate, covering all medical expenses, respecting the surrogate’s privacy and well-being, accepting the pregnancy’s outcome, and committing to raising the child. In turn, the surrogate must follow medical guidelines, attend prenatal care, maintain communication with the intended parent, and deliver the child immediately after birth, unless otherwise agreed.

Healthcare facilities offering ART services must provide information and counseling to both intended parents and surrogates, perform embryo transfers, maintain accurate records, and ensure confidentiality.

Before seeking ART services, both parties must formalize their agreement

with a notary.

The bill mandates written consent for the use of donated gametes (sperm or eggs) from both the donor and the receiving couple.

Children born through ART are entitled to the same legal rights as naturally born children.

The Ministry of Health will serve as the regulatory authority, authorizing healthcare facilities to provide ART services in Rwanda.

If passed, this law will significantly advance reproductive healthcare in Rwanda, supporting couples facing fertility challenges and establishing a regulated framework for ART.

NEWS UPDATES

HOSPITALS

Ezulwini Private Hospital receives COHSASA accreditation

ESWATINI — Ezulwini Private Hospital, an 87-bed facility located in Eswatini’s capital, Mbabane, has become the first hospital in the country to receive accreditation from the Council for Health Service Accreditation of Southern Africa (COHSASA).

The hospital achieved an impressive compliance rating of 93 and was awarded a two-year accreditation for

INVESTMENTS

meeting the rigorous standards of quality healthcare.

Ms. Jacqui Stewart, CEO of COHSASA, celebrated this milestone, recognizing the hospital’s commitment to providing safe, high-quality care.

She explained that the hospital began working towards COHSASA accreditation immediately after opening its doors, emphasizing that patient safety and care are their top priorities.

In addition to Ezulwini Private Hospital’s achievement, COHSASA also announced the accreditation of two Cure Day Hospitals in South Africa— East London and Wilgeheuwel.

This brings the total number of accredited Cure Day Hospitals to nine out of twelve facilities, a significant accomplishment.

Other notable healthcare facilities that received COHSASA accreditation

include ARWYP Medical Centre (3 years), Cure Day Hospital East London (2 years), Cure Day Hospital Wilgeheuwel (3 years), Drakenstein Palliative Care Hospice (4 years), Zulwini Private Hospital (2 years), Helderberg Hospice (4 years), and St. Nicholas Hospital (Campbell Branch) (3 years).

The award confirms that a facility has successfully completed a comprehensive quality improvement program and complies with standards endorsed by the International Society for Quality in Health Care External Evaluation Association (ISQua-EEA), the global authority on healthcare quality.

COHSASA itself is accredited by ISQua-EEA, making it the only internationally recognized accrediting body for healthcare facilities in SubSaharan Africa.

African Development Bank pledges US$75M to boost Tanzania’s healthcare infrastructure

TANZANIA — The African Development Bank has approved a US$75 million loan to Tanzania for the second phase of its Centre of Excellence for Skills and Tertiary Education in Biomedical Sciences project.

The project’s total cost is estimated at US$83.3 million, with the Tanzanian government contributing US$8.33 million in counterpart funding.

This builds on the first phase of the project, which laid the foundation by constructing key facilities, such as administrative and training units, at the Mloganzila campus of the Muhimbili University of Health and Allied Sciences (MUHAS), one of East Africa’s leading Centres of Excellence in Biomedical Sciences.

This new project phase, which runs from 2025 to 2029, aims to enhance the country’s healthcare capacity by addressing cardiovascular disease, a

growing concern in Tanzania, the East African Community, and the wider continent.

The main goal of this initiative is to develop a skilled workforce capable of preventing and treating cardiovascular diseases through improved training and infrastructure.

This second phase of the project will include the construction of a 600-bed cardiology teaching hospital equipped with state-of-the-art medical technology.

In addition, it will train 120 university staff members and 100 students, ensuring that 45% of these trainees are women.

This will help create a local talent pool to address cardiovascular disease, reduce treatment costs, and improve the community’s access to healthcare services.

The project is part of a broader

effort to fully operationalise the Centre of Excellence for biomedical sciences training and cardiovascular disease treatment.

The long-term aim is to train a new generation of healthcare professionals in cardiovascular sciences, covering prevention, treatment, and rehabilitation.

The second training phase will build on the work done in the first phase, during which 38 MUHAS educators were trained to enhance their skills in these areas.

Moreover, the project will provide full scholarships to 20% of students, prioritizing young people from disadvantaged backgrounds, particularly women and individuals with disabilities. This inclusive approach will ensure that the project’s benefits extend to all segments of society.

WHO prequalifies new TB diagnostic test

SWITZERLAND — The World Health Organization (WHO) has granted prequalification to the Xpert® MTB/RIF Ultra, a significant milestone in the fight against tuberculosis (TB).

This molecular diagnostic test, developed by Cepheid Inc., is the first TB diagnostic and antibiotic susceptibility test to meet WHO’s rigorous prequalification standards for quality, safety, and performance.

Prequalification is a crucial step in ensuring global access to reliable and accurate TB diagnostics.

Unlike traditional WHO endorsement, which focuses on diagnostic accuracy and patient outcomes, prequalification requires a comprehensive evaluation of a product’s quality and safety.

This rigorous process enables countries to confidently deploy effective tools to combat TB, one of the world’s deadliest infectious diseases.

The Xpert® MTB/RIF Ultra is a

REGULATORY

nucleic acid amplification test (NAAT) designed for use with the GeneXpert® Instrument System.

It rapidly detects the genetic material of Mycobacterium tuberculosis, the bacteria causing TB, in sputum samples.

This rapid and precise testing, which takes only hours, can identify mutations linked to rifampicin resistance, a key marker of multidrug-resistant TB.

The test is particularly intended for individuals who have tested positive for pulmonary TB and have not yet started or only recently begun treatment.

WHO’s assessment of the Xpert® MTB/RIF Ultra relied on data provided by the manufacturer and a review conducted by Singapore’s Health Sciences Authority.

TB remains a major global health challenge, claiming over a million lives annually, primarily in low- and middleincome countries.

Early and accurate detection of TB,

especially drug-resistant strains, is essential for effectively controlling the disease.

To further expand access to quality TB diagnostics, WHO is currently evaluating seven additional TB tests, demonstrating its ongoing commitment to global health equity and innovation.

TB REMAINS A MAJOR GLOBAL HEALTH CHALLENGE, CLAIMING OVER A MILLION LIVES ANNUALLY, PRIMARILY IN LOW- AND MIDDLEINCOME COUNTRIES.

Bayer recalls Yaz Plus birth control pills due to packaging mix-up

SOUTH AFRICA - Pharmaceutical giant Bayer, in collaboration with the South African Health Products Regulatory Authority (SAHPRA), has announced a nationwide recall of Yaz Plus birth control pills.

The recall affects a specific batch, identified as Batch WEW96J, which has an expiry date of March 2026 following a packaging error discovered in some

packs at retail pharmacies.

Some of the Yaz Plus packs mistakenly contained 24 light orange hormone-free tablets and only 4 pink, hormone-containing tablets.

This arrangement deviates from the correct configuration, which should have 24 pink hormone-containing tablets and 4 light orange hormone-free tablets.

This mistake compromises the contraceptive efficacy of the product, potentially leaving users without the expected protection.

The company has identified the root cause of the error and implemented corrective actions to prevent future occurrences.

Healthcare professionals, pharmacies, and patients with the affected batch have been urged to stop

using the product immediately.

Bayer has also advised customers to return the packs to the pharmacy or healthcare facility where they were dispensed for a replacement or credit.

For those who have already used the tablets from the recalled batch, Bayer has recommended consulting a healthcare provider promptly to discuss contraceptive coverage and any related concerns.

As a precautionary measure, the company has advised users not to take any tablets from the affected packs until they have sought professional medical advice.

Patients have also been reminded to inspect all their Yaz Plus packs and contact their healthcare providers if they have any doubts or experience issues related to the product.

EVENT REVIEW

National Cancer Summit

2nd (TAMC) Annual Transforming Africa MedTech Conference

Meditech innovators converged in Nairobi at Kempinski Hotel for a Three - day conference from August 28th -30th 2024, to chat the way forward the future of Medical Technology, especially on its role on delivery of quality healthcare.The event served as a premier platform for stakeholders to converge, collaborate, and refine strategies aimed at leveraging medical technology for meaningful progress in healthcare.

Event organizer, Wilfred Njagi, Co-Founder and CEO of Villgro Africa underscored the importance of supporting locally manufactured medical devices, highlighting the significant. “For too long, we have sent patients to India and other medically advanced countries, exporting money and resources in exchange for medical attention, despite our capacity to build and advance our own systems.”

Industry stakeholders at the conference addressed both the challenges and opportunities in advancing MedTech in Africa, emphasizing the critical need for local solutions through locally manufactured devices. The TAMC 2024 dialogue among stakeholders is set to shape the future of African healthcare, driving innovation, investment, and collaboration that will ultimately improve healthcare outcomes for millions.

2-4 February, 2023 – Nairobi, Kenya 28th - 30th AUG, 2024 – Nairobi, Kenya

Dawa Life Sciences

Three decades of transforming healthcare in East and Southern Africa

By ALPHONSE OKOTH

In Africa’s healthcare landscape, Dawa Life Sciences stands as a powerful testament to resilience, a vision driven by purpose, and a heartfelt commitment to its community.

Over its 30-year journey, Dawa Life Sciences has transformed from a modest pharmaceutical importer into a leading local manufacturer, a lifeline for patients who need quality medicines, and a catalyst for change within Kenya and beyond.

Dawa Life Sciences is more than a company for healthcare professionals—it is a story of dedication, challenges, and impact. In an interview with Healthcare Middle East & Africa magazine, COO Arjun Mohindra shares Dawa’s path, exploring its grassroots beginnings, community partnerships, and the innovative spirit that has propelled it forward.

Since its inception, this Kenyan-based pharmaceutical giant has not only provided affordable medicines but has also woven a narrative of resilience, innovation, and compassion for the communities it serves.

"We ask ourselves every day: Would we give this medicine to our mother, our father, or our child?" says Arjun. This question defines Dawa’s unwavering commitment to quality, a philosophy that resonates throughout its journey from a humble importer to a manufacturing powerhouse.

FROM A DINING ROOM DREAM TO A MANUFACTURING POWERHOUSE

Dawa’s story began humbly in 1994, not in a gleaming office but around a dining table in Kenya. Founded by Dr. Raju Mohindra and Dr. Ajay Patel, Dawa Life Sciences was born out of

a realization that Kenya and much of East Africa needed access to affordable, quality medication. The founders saw a glaring gap: high medication prices from multinational companies had left many people unable to afford essential medicines. With a passion to serve and a vision to create a better future, they started small but with immense resolve.

The breakthrough came in 2004 when the founders acquired Dawa Pharmaceuticals, moving from importer to manufacturer and creating a home-grown supply chain for East Africa. In those early days, Dr. Raju and Dr. Ajay would often work long hours, working alongside their team to ensure the production met strict quality standards. This transition laid the foundation for what is now one of the regions’s largest pharmaceutical companies.

. Today, Dawa Life Sciences operates three state-of-the-art facilities specializing in human medicine, penicillin production, and animal health and nutrition products.

The three facilities symbolize their growth and dedication to the region’s healthcare needs.

ANCHORED IN COMMUNITY: CREATING JOBS, IMPROVING HEALTH, AND BUILDING TRUST

For Dawa, being a pharmaceutical leader is about more than business. It’s about impact, building relationships and giving back to the community. Dawa employs over 650 team members across Kenya and the markets it operates in, with many employees having started their journey with the company decades ago.

Among the staff are inspiring stories, like that

SENIOR MANAGEMENT

TEAM AT DAWA LIFE SCIENCES

of a cleaner hired in the late 1990s who worked her way up to manage one of Dawa’s largest sales accounts. "Her journey is a testament to what we value—our people," the COO shares. These success stories speak to a company that values growth, not just in profits, but in people.

Dawa has also invested in creating accessible healthcare for local communities. Recently, they partnered with Ilara Health to establish a community clinic at their pharmaceutical facility in Baba Dogo Road, Ruaraka. Offering affordable medical services and Dawa’s own medicines at reduced costs, the clinic is part of Dawa’s belief in making healthcare accessible to all. "The clinic is a response to what we heard directly from our staff and neighbors—they need accessible, quality healthcare. The community clinic is set to be opened by January 2025, " the COO shares. The company's initiative goes beyond treating patients—it’s about providing dignity, respect, and support to those who need it most.

BRINGING HEALTHCARE HOME

Dawa’s strength lies in its understanding of healthcare needs. The company’s portfolio spans dermatology, gastroenterology, diabetes, and cardiology. Recently, Dawa introduced affordable

diabetes medications in response to the region's alarming rise in diabetes cases, which can be attributed to lifestyle changes.

“Lifestyle changes and diet are driving a surge in diabetes cases, yet the cost of medication remains a barrier,” explains the COO. “We’ve introduced quality diabetes drugs that are up to 30% more affordable, ensuring more patients can access treatment.”

Cardiology is another area in which Dawa has made significant strides. The company aims to address the growing burden of heart disease in the region by introducing new cardio-metabolic drugs and focusing on advanced formulations. "Diabetes medication is out of reach for many," says the COO, Arjun. "We launched a range of comparable quality drugs but significantly more affordable." Similarly, Dawa has been a key player in cardiology for over a decade, offering new, quality formulations that meet the evolving needs of patients.

Dawa’s impact extends far beyond Kenya. The company exports to over ten countries, reaching communities 2,000 kilometers away. Partnerships with organizations like the United Nations and USAID have further amplified its reach. "Supplying antimalarial products to

regions like Cameroon and Ethiopia through these partnerships makes us incredibly proud," the COO adds.

WHY DAWA’S STANDARDS SET THEM APART

To Dawa, quality is personal. Speaking with evident pride, Mr Arjun Mohindra explains their guiding philosophy: “Would you give this medication to your loved ones?” This simple question grounds Dawa’s commitment to quality. If a product isn’t good enough for a loved one, it isn’t good enough for their customers. This ethos drives every step of production, from sourcing raw materials to the rigorous testing protocols that ensure each batch is safe and effective.

Dawa’s commitment to quality has earned it a respected reputation in Eastern and Southern Africa. It has secured approvals from regulatory bodies like the Kenyan Pharmacy and Poisons Board, the Tanzania Medicines and Medical Devices Authority, and the Uganda National Drug Authority. The company adheres to stringent Good Manufacturing Practices (GMP), ensuring that every product meets international standards.

DAWA

LIFE

SCIENCES

OPERATES THREE STATE-OF-THE-ART FACILITIES SPECIALIZING IN HUMAN MEDICINE, PENICILLIN PRODUCTION, AND ANIMAL HEALTH AND NUTRITION PRODUCTS.

"Quality isn’t negotiable," the COO emphasizes. It’s about trust—and trust is something we’ve earned from our partners over the years." Despite being far from the world's major pharmaceutical hubs, Dawa’s standards remain uncompromised, reflecting a rare but deeply valued commitment. For healthcare providers, Dawa has become a trusted partner, a local name they can rely on for

medicines that meet international quality standards.

THE CHALLENGES OF LOCAL MANUFACTURING

Operating in East Africa comes with challenges, and Dawa’s journey hasn’t been without obstacles. Supply chain issues are among the most significant. “It’s frustrating at times,” admits the COO. “A shipment that takes a week to deliver in India can take over a month here. But we’re committed to overcoming these challenges because we believe in the potential of local manufacturing.”

These delays can disrupt production timelines, creating a ripple effect that impacts the availability and accessibility of medicines. But Dawa has learned to adapt, building local supply chains and strategic partnerships to mitigate these challenges. "Our job is to ensure that no delay, however inevitable, compromises the availability of life-saving drugs,” he asserts.

The company also grapples with regulatory disparities. While some African countries have made strides in harmonizing standards, others remain semi-regulated, creating a perception that Africa does not demand the same quality as global markets. “We constantly push for higher standards,” he adds. “We want African patients to receive the same quality of care as anyone else.”

Another obstacle, however, is perception. African-made pharmaceuticals are often seen as inferior, a view that Dawa has worked tirelessly to change. They know quality isn’t about location but commitment, processes, and integrity. By maintaining high standards and advocating for pharmaceutical excellence, Dawa Life Sciences is helping to shift this outdated view and pave the way for other local manufacturers.

EMBRACING SUSTAINABILITY AND REDEFINING

CORPORATE RESPONSIBILITY

Dawa’s commitment to the community extends to the

environment, with sustainability initiatives that reflect a company's thinking not just of the present but of the future. From developing solar panels that will soon supply 30% of their energy needs to extensive tree-planting campaigns, Dawa is integrating eco-friendly practices into its operations. "This isn’t just about reducing costs; it’s about reducing our carbon footprint," says the COO.

They’ve also made strides in waste management, recognizing the importance of responsible disposal and recycling in healthcare manufacturing. These initiatives aren’t just checkboxes but part of Dawa’s identity. In fact, Dawa has involved its employees in these projects, organizing treeplanting days and encouraging staff to be part of the change. For healthcare providers and patients, knowing that Dawa is committed to environmental and human health adds a new dimension of trust and respect.

PUSHING BOUNDARIES TO SERVE BETTER

The COVID-19 pandemic accelerated Dawa’s adoption of digital technologies, reshaping how it operates and engages with stakeholders. The company now uses real-time production tracking, business intelligence platforms, and even AI for customer interactions. “Every 10 minutes, our system updates us on production output. This level of precision ensures we meet demand efficiently,” Mr Arjun Mohindra explains.

For customer engagement, Dawa has introduced AI-driven solutions to handle basic inquiries, allowing human agents to focus on complex cases. These innovations are not just about efficiency but also about enhancing customer experience.

A vision for the future of African healthcare

As Dawa Life Sciences celebrates 30 years of excellence, its vision remains bold and ambitious: to be the reference for life sciences in Africa. Dawa looks to expand into new markets, deepen its product portfolio, and advocate for higher regulatory standards across Africa. “Our goal is to become the reference point for life sciences in Africa,” says the COO. “Not the biggest, but the best in quality, service, and impact.”

Dawa’s leadership team, with an average age of just 35, is driven by a youthful energy that matches this vision. They blend experience with fresh perspectives to ensure the company remains adaptable and forward-thinking.

The company is also exploring advanced manufacturing technologies and international certifications to enhance its credibility further. With these goals in mind, Dawa is positioning itself as a life sciences company and a cornerstone of East and Southern African healthcare.

For healthcare professionals, Dawa Life Sciences is a reliable supplier and a partner in improving health outcomes. As the company looks to the future, its commitment to affordable, high-quality medicines and community impact serves as a beacon of hope for East Africa and beyond. “In the end, it’s about the lives we touch,” concludes the COO with a smile. “That’s what keeps us going.” HCMEA

AGC TENWEK HOSPITAL

A legacy of compassionate care and advanced medical services

By ALPHONSE OKOTH

HMR. BENJAMIN

SIELE, ACTING CEO OF AGC

TENWEK HOSPITAL

igh in the lush hills of Bomet County, Kenya, AGC Tenwek Hospital stands as a life-changing refuge for thousands seeking hope and healing. Established in the 1930s by missionaries from the World Gospel Mission, AGC Tenwek began with a simple but powerful purpose: to serve the physical and spiritual needs of people in need.

Today, that humble mission has grown into a premier healthcare institution in East Africa, where faith-driven compassion and advanced medical care coexist. For many, Tenwek is more than a hospital; it’s a sanctuary of support and care, a place where lives are transformed by a community deeply committed to service.

A TRADITION OF COMPASSIONATE, HOLISTIC CARE

Compassionate care is woven into Tenwek Hospital's very foundation. Acting CEO Mr. Benjamin Siele reflects on the hospital’s guiding philosophy: “Our founders saw healthcare as more than treating illnesses; it was about caring for the whole person—body, mind, and spirit.” This ethos lives on today in Tenwek’s holistic approach to treatment, where addressing emotional and spiritual needs is as important as

the physical.

One way Tenwek achieves this balance is through its chaplaincy program, which serves as a source of comfort to patients and their families. Chaplains join doctors and nurses on rounds, offering spiritual guidance and emotional support to patients in vulnerable moments. “We want our patients to feel the love of Christ through our care,” Siele shares.

This holistic approach has earned Tenwek a reputation not only for medical excellence but for its role as a place of peace, renewal, and hope. Patients often speak of finding relief and strength in this faith-based environment, where they feel genuinely cared for in mind, body, and soul.

GROWING EXPERTISE AND A FAR REACHING IMPACT

Over the decades, Tenwek has expanded both its facilities and its impact, responding to growing demands for specialized medical services. The hospital now operates as a critical training and research hub, hosting one of East Africa’s most advanced cardiothoracic centers, the CardioThoracic Center (CTC). Here, Dr. Russ White, a seasoned cardiothoracic surgeon, has dedicated his career to tackling complex heart and chest conditions, a focus inspired by his early days at Tenwek.

Dr. White arrived at Tenwek in 1992, drawn to the hospital’s mission and aware of the critical health challenges facing the region. “Patients would come in with esophageal cancer, and there was little we could offer them beyond a feeding tube,” Dr. White recalls.

Over the years, as he treated patients with heart disease, he saw the need for advanced cardiothoracic care that simply didn’t exist in Kenya. “The demand was there, but the resources weren’t,” he reflects. With a determination to bridge that gap, Dr. White and Tenwek’s team began envisioning a center dedicated to addressing complex heart and chest issues.

THE CARDIOTHORACIC CENTER: A LIFELINE FOR HEART HEALTH IN KENYA

Recently, the hospital commissioned the CardioThoracic Center (CTC), a testament to compassion-driven innovation in healthcare. This world-class facility, led by Dr.White, is set to transform heart and chest care in East Africa. For years, Dr. White and the Tenwek team have envisioned a center that could address the severe shortage of cardiothoracic care in

Kenya, providing affordable life-saving surgeries, advanced diagnostics, and an innovative training hub for the next generation of specialists.

The Cardio Thoracic Center was conceived to meet these demands, built on a foundation of care for the most vulnerable. But turning that vision into reality wasn’t easy. “It was clear that our current facilities were insufficient. Each week, we lost patients waiting for surgery. We needed a center that could handle the volume and complexity of cases we were seeing,” Dr. White shares.

With support from Samaritan’s Purse, a U.S.-based humanitarian organization, Tenwek undertook an ambitious project: a state-of-the-art, 400,000-square-foot facility. The center features seven operating rooms, a cardiac catheterization lab, endoscopy suites, and housing for trainees—all designed to treat patients with heart and chest diseases and to support the education of Kenya’s next generation of surgeons, nurses, and perfusionists.

The cost of building the CTC totaled around KES 5 billion (about US$35 million), and its completion represents an increase in surgical capacity and a powerful commitment to compassionate, equitable care. “The fact that we can now provide minimally invasive surgery, cardiac catheterization, and complex thoracic operations is a game-changer,” Dr. White says, his voice tinged with pride and relief.

ADDRESSING A HEALTH CRISIS: RHEUMATIC HEART DISEASE AND CANCER CARE

For Dr. White and his team, the mission of the CTC is personal and pressing. Rheumatic heart disease, often called “the

neglected disease of the neglected,” is a serious health threat in Kenya. A bacterial infection often acquired in childhood, it damages the heart valves over time, leaving many young people in need of life-saving surgery. To make matters worse, rheumatic heart disease primarily affects individuals in lowincome regions, where resources are scarce and treatment costs are often out of reach.

To address this, Tenwek launched school-based screenings across Bomet County, allowing for early detection and treatment. “If we catch these cases early, we can treat them with medication and potentially avoid surgery altogether,” Dr. White explains. However, even with preventative care, many young people require surgery to survive. The CTC is currently meeting the demands of hundreds of patients, but with a waiting list of 850 individuals, the need continues to exceed capacity. “Every week, we lose someone on that list,” Dr. White says quietly. “It’s heartbreaking, but it reminds us of why we’re here.”

The CTC also addresses esophageal cancer, one of the most prevalent cancers among Kenyan men. The high cost of diagnostic tests prevents many patients from seeking help until it’s too late. Dr. White and the Tenwek team are advocating for policy changes to make early diagnostics more accessible, a step they hope will save lives. “Most patients come to us when it’s too late to operate,” Dr. White explains. National health policies currently exclude esophageal cancer diagnostics from coverage, and the financial burden falls heavily on patients. By lobbying for change and offering direct support, Tenwek hopes to reduce this burden and improve survival rates.

OUR FOUNDERS SAW HEALTHCARE AS MORE THAN TREATING ILLNESSES; IT WAS ABOUT CARING FOR THE WHOLE PERSON—BODY, MIND AND SPIRIT.

Mr. Benjamin Siele - Acting CEO AGC Tenwek

A HUB FOR ADVANCED TRAINING AND INNOVATION

The CTC is not only a medical facility but also a training center that will leave a lasting impact on Kenya’s healthcare system. Dr. White envisions the center as “the premier training institution for cardiothoracic care in the region.” At Tenwek, surgeons, critical care nurses, perfusionists, and soon, cardiologists, will have access to advanced training and equipment. With an initial staff of 300, the CTC plans to increase its workforce to 1,000 as demand grows.

these screenings, we’re not only helping those in immediate need but changing the future for countless others,” Dr. White adds.

The impact of Tenwek’s efforts is evident in the countless success stories shared by patients and their families. Dr. Agneta Odera, a surgeon at the CTC, remembers one young boy whose mother brought him to Tenwek after traveling from across East Africa. He had been turned away from multiple clinics due to the severity of his condition, which caused fainting spells and left his skin tinged blue. “We diagnosed his

AGC TENWEK HOSPITAL MEMBERS OF BOARD OF MANAGEMENT

Dr. White emphasizes the importance of this educational component: “Our goal is to create a skilled workforce capable of meeting the healthcare needs of Kenya and surrounding countries. We are building a legacy of trained specialists who can take these skills wherever they go, and serve communities that might otherwise lack access to quality healthcare.”

The center is also pioneering minimally invasive heart surgeries and other advanced procedures. For example, the new cardiac catheterization lab, the only one of its kind in Western Kenya, offers patients a non-surgical alternative for treating coronary artery disease. The introduction of these services represents a major leap forward for cardiothoracic care in Kenya and sets the CTC apart from other hospitals in the country.

Through school-based screenings and community outreach, the CTC also focuses on prevention. The team identifies young people with early signs of rheumatic heart disease and provides them with medications that can prevent the need for surgery later on. “With

condition and performed the surgery he needed,” Dr. Agneta recounts. “Today, he’s in nursery school and thriving.” Stories like his highlight the CTC’s role as a true lifeline, one that offers hope to families who have exhausted every other option.

BALANCING AFFORDABILITY WITH SUSTAINABILITY

Operating a state-of-the-art facility like the CTC requires substantial financial resources. While approximately 70% of Tenwek’s revenue comes from the Kenyan National Hospital Insurance Fund (NHIF), delays in reimbursements frequently strain the hospital’s finances. Tenwek is currently owed nearly KES 600 million by the NHIF, a figure that impacts the hospital’s ability to maintain services. “The NHIF reimburses months after the fact, making it challenging to keep our doors open,” Siele explains.

A new hope comes with the introduction of the Social Health Authority (SHA), which promises to increase healthcare coverage for lifesaving treatments. “If SHA fulfills its promise, we could see nearly full coverage for heart surgeries, a massive relief for many of our patients,” Dr. White notes. This shift could allow the CTC to double its capacity and make critical care more accessible to families struggling with medical costs.

Tenwek also relies on community support

and partnerships with organizations like Friends of Tenwek, a U.S.-based charitable organization that raises funds for low-income patients. In addition, Tenwek organizes events such as the “Hearts in Motion Marathon,” attracting participants from across the region to raise funds that ensure affordable treatment for all who need it. Through these initiatives, Tenwek reinforces its commitment to providing high-quality healthcare, regardless of patients’ financial circumstances.

EXPANDING ACCESS TO CARE ACROSS KENYA

As Tenwek expands, the hospital is establishing satellite clinics in Nairobi, Kisumu, and other urban centers to increase access to specialized care. These clinics will allow patients to receive preliminary consultations closer to home, making advanced care accessible to thousands more. “Our goal is to support patients wherever they live, so they don’t have to travel far for essential treatment,” Siele explains.

Tenwek is also venturing into telemedicine, allowing healthcare providers to conduct followup consultations for patients in remote areas. This approach enhances care continuity, making Tenwek a leader in leveraging technology to overcome healthcare access barriers.

With its ever-expanding reach, the hospital is poised to serve as a model for similar facilities across Africa. Dr. White shares, “The Cardiothoracic Center is not just a building; it’s a

DR. RUSS WHITE, LEADING SURGEON AT CTC CENTRE

promise to our community. It represents our commitment to providing world-class care to everyone who needs it.”

RESILIENCE THROUGH PARTNERSHIP AND INNOVATION

Despite the complexities of healthcare delivery, Tenwek’s commitment to compassionate and holistic care is unwavering. Partnerships with organizations like Samaritan’s Purse and Friends of Tenwek have enabled the hospital to build advanced facilities, fund treatment for low-income patients, and provide life-saving surgeries that would otherwise be inaccessible.

Tenwek’s innovations in minimally invasive surgeries, preventative care, and community outreach are reshaping healthcare in East Africa. One remarkable story is of a mother who traveled from Sierra Leone with her child, who had been turned away from numerous clinics. The child’s condition, causing fainting spells and a bluish skin tint, was finally diagnosed and treated at Tenwek’s CTC. “Today, that child is healthy and thriving in nursery school,” Dr. Agneta shares. “These are the stories that drive our work.”

THE HEART OF TENWEK’S MISSION: A TEAM EFFORT

Tenwek’s success is built on the dedication of its diverse team, including surgeons, nurses, administrators, and support staff who bring Dr. White’s vision to life. For Dr. Agneta, healthcare at Tenwek is a collective mission. “This work isn’t about a single person. It takes a dedicated team of surgeons, nurses, administrators, and support staff,” she says. “We’re all here because we believe that everyone deserves access to quality care.” The center’s success is the result of countless hours and the dedication of a team that believes in Tenwek’s vision.

Tenwek Hospital’s Cardio Thoracic Center is more than a building; it’s a promise to care for the underserved, to build up

a new generation of healthcare providers, and to transform lives. As Dr. Agneta reflects, “Our patients just want a chance to live—to go to school, to have a family, to be part of their communities. And it’s our privilege to make that possible.” Through their work, Tenwek’s team has created a sanctuary of healing, one that gives families the hope of a brighter, healthier future.

Dr. White and his team have plans to introduce robotic heart surgeries and eventually launch a heart transplant program, a venture that reflects Tenwek’s ambitious yet deeply rooted commitment to its mission. “It may sound ambitious, but we know the need is real, and with the right resources, we can meet it,” Dr. White asserts.

A VISION FOR THE FUTURE

Tenwek’s journey has not been without challenges, but its staff's resilience, community support, and unwavering commitment to its mission have propelled the hospital forward. The hospital is a living testament to the transformative power of compassionate care, standing as a model for healthcare facilities across Africa.

AGC Tenwek Hospital embodies a legacy of hope, compassion, and excellence in healthcare. Through its holistic approach to patient care, community outreach, and education, it has not only changed the lives of countless individuals but has also strengthened the fabric of the communities it serves.

As it continues to navigate the complexities of healthcare delivery in a rapidly changing environment, Tenwek remains steadfast in its commitment to its founding principles. For many, it is not just a place to receive medical treatment; it is a place of healing, faith, and empowerment—a true sanctuary where lives are transformed one patient at a time. HCMEA

Located in the Radisson Blu Hotel Upper Hill, Revitalize Wellness Center offers various services, including a spa, salon, mani-pedi section, fully equipped gym, group fitness classes, nutritionist consultations, and a juice and coffee bar.

SPAS AND WELLNESS CENTERS IN KENYA

Yoga at Watamu Treehouse 5

Located just outside of Nairobi, Entim Sidai is a five-star wellness center offering a holistic approach to health and relaxation. The spa features a variety of treatments, yoga and meditation classes, and a beautiful environment surrounded by nature.

Serenity Spa, with locations in Gigiri, Kitisuru, Karen, and Tigoni, is Nairobi’s premier destination for holistic wellness and beauty treatments. Each spa features luxurious amenities such as steam treatments, saunas, a nail bar, and specialized anti-aging treatments like micro-needling and bespoke detox programs.

Shaanti Holistic Health Retreat, located in Groganville Estate, Nairobi, features a range of therapies, including hydrotherapy, aromatherapy, hot stone therapy, body scrubs, and facials.

Yoga at Watamu Treehouse offers a unique retreat experience on Kenya’s beautiful coastline. The retreat’s holistic approach integrates yoga with meditation, breathwork, and mindfulness practices, promoting overall well-being.

Wild Earth Day Spa, nestled in the vibrant Westlands district on Peponi Road, Nairobi, offers a serene escape from the urban hustle. Inspired by Moroccan design, their spa is a haven of relaxation, rejuvenation, and sensory delight. Wild

Nestled on the idyllic Kenyan coast at Watamu, Wildfitness Kenya emphasizes primal movements –jumping, climbing, crawling – that are as fun as they are effective.

Wildfitness Kenya has been recognized as one of the world’s top fitness boot camp destinations.

Dojo has in-house physiotherapists and masseuses, they support holistic wellbeing, ensuring our members heal, restore, and maintain their bodies at optimal levels. Thir Revive Bar, steam rooms, saunas, and relaxation spaces are carefully crafted to complement your workout experience.

Kempinski The Spa epitomizes luxury and rejuvenation, offering tranquility and indulgence in select Kempinski hotels worldwide. With a commitment to holistic wellness, Kempinski The Spa offers an array of signature treatments, including massages, facials, body wraps, and beauty rituals, tailored to individual needs and preferences.

Afya Bora Spa is a sanctuary of wellness and rejuvenation that promotes holistic health and vitality. The spa’s expert therapists are committed to providing personalized care and attention, ensuring that every visit is a transformative journey toward optimal wellness.

The voice for medically underserved populations in Kenya RUPHA: ASSOCIATION FOCUS

By JACKIE MUINDE

Founded in March 2020, the Rural & Urban Private Hospitals Association of Kenya (RUPHA) is a nonprofit organization representing private Health Facilities located in rural areas and urban Health Facilities serving medically underserved populations (MUP’s) of Kenya.

Healthcare Middle East and Africa Magazine had a sit down with the Founding Chairman Dr. Brian Lishenga, a medical doctor with 18 years of experience in healthcare who specializes as a family physician and medical physiologist.

HCMEA: When did discussions about forming the RUPHA coalition among rural hospitals begin?

DR LISHENGA: Discussions started around April 2019 when rural hospital owners were concerned about proposals from the Kenya Association of Private Hospitals (KAPH), particularly limiting outpatient visits covered by NHIF to four per year. This proposal was seen as unfavorable for rural hospitals where many patients often relied heavily on these visits and had no other insurance coverage options.

Initially, the coalition was informal, with around 12 hospitals forming a WhatsApp group to discuss their issues and share information. The group quickly grew as more hospital owners joined through word of mouth. By June 2019, we held the first Annual General Meeting (AGM), where we ratified a constitution and elected office bearers, formally establishing the Rural Private Hospital Association of Kenya (RUPHA).

Over time, some urban hospital providers felt aligned with RUPHA’s advocacy and requested to join. This led to a name change from a purely rural-focused association to the Rural Urban Private Hospital Association, accommodating both rural and urban members.

HCMEA: How has RUPHA managed to grow its membership and visibility?

DR LISHENGA: RUPHA has expanded through word of mouth, effective use of social media (mainly WhatsApp), and increased public visibility via media advocacy. They have also enhanced their membership process by providing a userfriendly online registration system for interested hospitals.

MEMBERSHIP

HCMEA: How many hospitals are RUPHA members currently, and how widespread is its coverage?

DR LISHENGA: Currently, RUPHA has close to 400 member hospitals and covers approximately 43 counties in Kenya. However, it has limited presence in regions where the private healthcare sector is less developed, such as Moyale, Mandera, Wajir, and Samburu.

HCMEA: How does a hospital become a member of RUPHA?

DR LISHENGA: Hospitals can join RUPHA through a straightforward process. They must be registered with relevant regulatory bodies like the Kenya Medical Practitioners and Dentists Council (KMPDC). The hospital submits necessary documents via RUPHA’s website for verification. Membership is institutional, meaning it remains with the hospital regardless of changes in ownership.

Dr. Lishenga’s journey in medicine, advocacy, and leadership

Dr. Lishenga’s medical journey began at the University of Nairobi, where he earned his undergraduate degree in Medicine and Surgery in 2006. He furthered his expertise with a Master of Science in Medical Physiology from the same institution (2009–2013) and later pursued a Master’s in Family Medicine at the University of Edinburgh, Scotland (2017–2020).

As a family physician, Dr. Lishenga emphasizes comprehensive, lifelong care for patients. “Family Medicine focuses on holistic healthcare from ‘cradle to grave,’” he explains. By building long-term relationships, family physicians address patients’ medical history, environmental factors, and familial contexts, managing acute and chronic illnesses while advocating for community health. This approach contrasts with specialized fields like surgery or obstetrics, offering continuity and care across all life stages.

In addition to clinical practice, Dr. Lishenga has dedicated over 15 years to teaching Medical Physiology at Egerton University. “Medical Physiology bridges science and medicine,” he shares. This academic foundation has enabled him to blend teaching, research, and practice seamlessly. While his focus now leans toward advocacy and teaching, he continues to draw on his clinical experience to inform his work.

Dr. Lishenga’s foray into advocacy began in 2010 when he co-founded a medical outpatient center in Nakuru with a team

HCMEA: What does the association offer to its members?

DR LISHENGA: The association provides several key services to its members, categorized into five main areas:

· ADVOCACY FOR HEALTHCARE EQUITY

The association speaks for healthcare providers, particularly those in areas with a shortage of health professionals (e.g., doctors, nurses, mental health specialists). The association ensures representation in policy discussions with organizations influencing healthcare, such as the Ministry of Health, Treasury, and various parastatals. It also engages with support organizations like the Bill Gates Foundation for projects that target underserved populations.

· INFLUENCE ON PAYMENT SYSTEMS AND REIMBURSEMENTS

The association works to innovate and improve payment mechanisms and timely reimbursements to healthcare providers. It also intervenes on behalf of individual healthcare facilities experiencing reimbursement issues, supporting efficiency at the branch level of organizations like NHIF.

of specialists. Though the clinic was a success, his colleagues eventually moved on, leaving him in Nakuru while teaching at Egerton University in nearby Njoro. Observing limited healthcare options in the area, he founded New Point Hospital, initially a small outpatient clinic.

The hospital’s growth mirrored community demand. From closing at 6 p.m., operations soon expanded to 24/7 services. By 2018, New Point had evolved into a fully functional Level 4 hospital with surgical capabilities and 30 beds.

Recognizing the systemic inequities, Dr. Lishenga joined the Kenya Association of Private Hospitals (KAPH) in 2018 to advocate for policy reforms. His efforts focused on equitable NHIF compensation rates and incentives to attract skilled healthcare workers to rural areas. “I pushed for higher reimbursement rates akin to a hardship allowance for rural hospitals,” he recalls.

Dr. Lishenga’s advocacy has propelled him into leadership roles within KAPH, where he continues to influence healthcare policy. His vision includes creating sustainable systems that ensure rural communities receive quality healthcare while supporting private providers in underserved areas.

By blending his expertise in medicine, teaching, and advocacy, Dr. Lishenga exemplifies a commitment to transforming healthcare in Kenya, ensuring that even the most remote communities have access to equitable and quality care.

· PARTNERSHIP DEVELOPMENT

The association facilitates linkages between its members and industry stakeholders, such as banks, equipment manufacturers, pharmaceutical companies, and service providers. It also supports collaborative efforts, such as advertising opportunities, and builds networks for mutual benefit.

· MEMBER EDUCATION AND TRAINING

The association provides training and educational support to help members make informed decisions about growth areas, such as fertility services or customer care improvements. It offers technical assistance on infection control, financial management, HR, and policy updates, particularly regarding changes in health insurance schemes.

· ECONOMIC EMPOWERMENT THROUGH GROUP PURCHASING

The association has established the RUPHA Drug Agency (RDA), a group purchasing organization aimed at negotiating better prices for commodities by leveraging economies of scale. It allows members to access lower prices for pharmaceuticals

and other supplies by pooling their purchasing power.

RUPHA DRUG AGENCY (RDA), RUPHA SOFT AND RUPHA AFYA BORA

HCMEA: What is the RUPHA Drug Agency (RDA), and how does it benefit members?

DR LISHENGA: The RUPHA Drug Agency (RDA) is a group purchasing organization created by the association to negotiate better prices for medical supplies and pharmaceuticals. By pooling the purchasing power of its members, RDA helps lower costs, making essential healthcare products more affordable for private sector hospitals.

The goal is to create a similar setup to Kenya Medical Supplies Authority (KEMSA) which is for public hospitals, or Mission for Essential Drugs and Supplies (MEDS), which is for faith based health units, but for the private sector, reducing costs and increasing access to essential medical supplies.

HCMEA: What is RUPHA Soft and why was it developed?

DR LISHENGA: RUPHA Soft is a digital hospital management information system (HMIS) created by RUPHA Afya Bora, a company under the RUPHA umbrella. It was developed in response to the increasing demand for digitization in healthcare, with a specific focus on addressing the challenges faced by hospitals in adopting and maintaining digital systems. Many hospitals struggled with high costs and frequent changes in HMIS software, prompting RUPHA to create a cost-effective solution tailored to their needs.

HCMEA: What problem does RUPHA Soft aim to solve for healthcare providers?

DR LISHENGA: RUPHA Soft addresses several issues, including the high cost of acquiring and maintaining HMIS software. It aims to provide a stable, user-friendly, and efficient digital platform that hospitals can use to manage patient records, inventory, financials, and claims without frequent disruptions or high expenses.

RUPHA partnered with Amazon Web Services (AWS) through the Amazon Health Equity Fund, which provides access to advanced cloud infrastructure. This collaboration allowed RUPHA to develop a sophisticated HMIS tailored to the needs of Kenyan healthcare providers without incurring direct financial costs. It is also built to align with the Kenyan government’s Digital Superhighway initiative,

making it compatible with national digital health infrastructure. Additionally, it is provided free of charge to RUPHA members.

The data collected via RUPHA Soft will be instrumental in analyzing disease patterns, patient demographics, drug usage, and healthcare delivery efficiency across the private sector. This information will help RUPHA negotiate better terms with suppliers, improve patient care, and potentially inform public health policy. By having access to real-time data, RUPHA can provide valuable insights into healthcare trends and needs in Kenya.

As of now, RUPHA Soft has been deployed in about seven hospitals. These facilities are fully operational with the software, managing tasks like ordering supplies, tracking inventory, and submitting electronic claims. The feedback has been positive, with ongoing user experience assessments to refine and enhance the system further.

HCMEA: What future plans does RUPHA have for RUPHA Soft?

DR LISHENGA: RUPHA aims to make RUPHA Soft the leading HMIS for the private sector in Kenya. We plan to expand its usage across their network of over 400 healthcare providers, ultimately covering up to 360,000 monthly patient visits. This extensive data collection will enable better insights into disease patterns, drug consumption, and healthcare needs, which can be used to negotiate better deals for providers and improve patient care.

HCMEA: How does RUPHA ensure data security and privacy with RUPHA Soft?

DR LISHENGA: Data security and privacy are top priorities for RUPHA Soft. It utilizes AWS, renowned for its high-level data protection, and complies with regulations from the Office of the Data Protection Commissioner in Kenya. RUPHA Soft has been built with strong data privacy protocols, and it is one of the few HMIS systems officially registered and certified for data protection in the country.

HCMEA: What is RUPHA Afya Bora, and how is it related to RUPHA Soft?

DR LISHENGA: RUPHA Afya Bora is the parent company behind RUPHA Soft. It initially aimed to create a health insurance product accessible through the RUPHA hospital network. However, before launching the insurance product, RUPHA Afya Bora focused on standardizing healthcare

services across its network to ensure consistent quality. RUPHA Soft plays a crucial role in this standardization by providing a unified digital platform for managing patient care and hospital operations.

The long-term vision of RUPHA Afya Bora is to build a reliable network of standardized healthcare providers capable of offering a comprehensive health insurance product to the mass market. By ensuring that hospitals across different regions deliver consistent quality of care through implementing RUPHA Soft and partnerships with standardization bodies like SafeCare, RUPHA Afya Bora aims to enhance patient trust and facilitate the rollout of a massmarket health insurance solution.

CHALLENGES FACED BY ADVOCACY WORK

HCMEA: What are the challenges faced by RUPHA in its advocacy work?

DR LISHENGA: RUPHA’s work is highly political, often leading to misunderstandings. For instance, when RUPHA proposed a shift to cash payments due to delayed NHIF reimbursements, it was perceived as a criticism of the government or specific individuals, even though it was a strategy to ensure hospital operations continued smoothly. Such actions can be seen as politically motivated, although they are driven by practical needs to maintain service delivery.

Secondly, advocacy is considered lonely because it often involves taking a stand that may not be popular or supported by all stakeholders. I, for example, face personal and professional risks, such as being labelled a “loose cannon,” which can lead to reluctance from others to engage or recommend hospitals affiliated with the association. This isolation is a significant challenge as it can hinder collaborations and partnerships.

One major challenge is balancing the interests of diverse members, especially when there are discrepancies in NHIF payments. For example, some NHIF branches delay quarterly hospital payments, causing financial strain. While most branches may be up to date, those affected feel neglected and expect RUPHA to take immediate action, such as organizing demonstrations. This creates tension, as RUPHA must carefully manage its advocacy efforts without causing conflict with NHIF or neglecting its members.

Financial challenges are significant for RUPHA, as their operations require resources.

Membership fees are minimal—KES2,000 (US$15.48) as a joining fee and KES12,000 (US$92.85) annually. While this is affordable compared to the value provided, some hospitals still struggle to pay due to tight budgets. This limits RUPHA’s ability to fund publicity, events, and projects, although the situation has improved since 2019 when they often used personal funds for activities.

FUTURE PLANS

HCMEA: What strategies does RUPHA envision for its future growth and influence in Kenya’s healthcare sector?

DR LISHENGA: RUPHA aims to unify and strengthen the private healthcare sector, which currently holds a 54% market share in Kenya. With only about 400 members (representing 20% of potential private healthcare providers), their goal is to increase membership to include all 2,000+ private facilities in the country. This expansion would create a powerful lobby capable of influencing healthcare policies and contract negotiations, promoting fair treatment for citizens and healthcare providers.

HCMEA: What long-term goals does RUPHA have for improving the quality of healthcare services?

DR LISHENGA: RUPHA’s vision includes enforcing higher standards among its members to ensure quality care. As the association grows stronger, it plans to hold hospitals accountable for patient treatment, addressing issues like abuse and negligence. By building a robust organization, RUPHA aims to make it costly for hospitals to provide substandard care, thus protecting patient rights and safeguarding healthcare providers’ interests.

HCMEA: How does RUPHA plan to address the fragmentation in Kenya’s healthcare sector?

DR LISHENGA: RUPHA aims to reduce fragmentation by uniting private healthcare providers under a single network. This would prevent “divide and rule” tactics, where unfavourable contracts are imposed on individual hospitals rather than negotiated collectively. By presenting a unified front, RUPHA hopes to achieve better terms for providers and patients, creating a more equitable and efficient healthcare system. HCMEA

A MIRACLE IN A DISH:The Power of IVF and the Future of the Family

By VINCENT MORANGA

The recent World Contraception Day, marked on September 26 under the theme “A choice for all. Freedom to plan, power to choose,” serves as a reminder of the often-overlooked issue of infertility. This global struggle affects millions of couples, posing a significant challenge to reproductive health. The World Health Organization (WHO) defines infertility as the failure to conceive following at least 12 months of regular, unprotected sexual intercourse, pointing to the need for equitable access to reproductive health care and family planning for all.

In terms of numbers, the World Fertility and Family Planning 2020 report shows that worldwide fertility fell from 3.2 to 2.5 live births per woman from 1990 to 2019. Furthermore, the WHO states that one in every six persons globally was infertile as of April 2023. Although infertility is considered a challenge, it can be treated with medicine, surgery, or assisted reproductive technologies such as in-vitro fertilization (IVF), in which an egg and sperm are fertilized in a lab dish and transferred to a womb as an embryo.

UAE'S RISE AS AN IVF HUB

Since the world’s first successful IVF birth in 1978, fertility medicine has made tremendous progress, giving individuals and couples new opportunities to realize their dreams of having a family. This remarkable progress instils hope and optimism, especially in the UAE, where the IVF market was valued at US$231.57 million in 2021 and is predicted to grow at a CAGR of 9.64% over the forecast period.

Given the increased awareness of the

importance of early detection, the UAE adoption of IVF to produce healthy infants with the option of family balance has had a favourable impact on the UAE’s IVF industry. This has established the UAE as a leader in providing IVF services, with major hospitals such as ART Fertility Clinics Abu Dhabi, King's College Hospital Dubai (KCH), American Hospital Dubai, Orchid Fertility Clinic, First IVF Clinic, and M42 Group's HealthPlus Fertility & Women's Health Center.

THE HIDDEN COST OF TRADITION

Infertility among women is highly prevalent in the UAE, with an estimated 90% of cases linked to vitamin D deficiency due to limited sun exposure. In cities such as Dubai, Abu Dhabi, Sharjah, and Al Ain, many Emirati women traditionally wear burqas or abayas outdoors, significantly reducing their exposure to sunlight. This lack of sun exposure limits the body’s production of vitamin D, a critical nutrient that influences the antiMullerian hormone (AMH), which is responsible for maintaining both the quantity and quality of eggs. Additionally, insufficient vitamin D levels may elevate cholesterol levels in women, adding further complications to fertility and pregnancy. Obesity and secondary infertility are other leading causes of infertility in Emirati women. According to the UAE's 2017-2018 National Health Survey, 67.9% of persons aged 18 to 69 are overweight or obese. In women, obesity results

in decreased uterine receptivity and poor egg quality. Secondary infertility, which occurs when it is difficult to become pregnant after conceiving for the first time, is also common.

UNDERSTANDING THE INFERTILITY JOURNEY

For many couples, the journey to parenthood begins with the painful reality of infertility.

The emotional toll is significant as couples endure a series of medical tests, consultations, and difficult decisions. This understanding and empathy are crucial in supporting couples through their IVF journey. According to Dr. Nadia Najjari, a Consultant in Reproductive Medicine and Infertility at HealthPlus Fertility Center, part of the M42 group, IVF is more than just a medical procedure; it is a shared experience requiring resilience and determination.

“Infertility is more common than many realize, and it can be an emotionally and physically challenging experience. The journey can be overwhelming, filled with medical appointments, tests, and tough choices,” explains Dr. Najjari.

THE IVF PROCESS EXPLAINED

IVF is a multifaceted process that involves collecting mature eggs from the ovaries and fertilizing them with sperm in a laboratory. Typically, the entire IVF cycle takes about four to six weeks, starting from the administration of fertility medication before egg retrieval until the patient is retested for pregnancy. Once fertilisation occurs, the embryo is transferred to the uterus, and pregnancy is established if it successfully implants into the uterine wall.

For women, IVF demands a significant physical effort, as it requires daily hormone injections and an egg retrieval procedure. This stage can be physically taxing, making emotional support from partners, family, and friends essential. In contrast, men may experience UAE IVF MARKET CAGR AS OF 2021 9.64% IN

ANTI - ABORTION ADVOCATES SUPPORTING ALABAMA RULING ON IVF

fewer visible physical challenges, but their role is equally crucial as they provide the sperm for fertilization, and in cases where male infertility is a factor, advanced treatments are available. The newly opened HOWA Men’s Health Clinic at HealthPlus Fertility offers personalized and compassionate care to men, aiming to optimize fertility outcomes for both partners.

THE POWER OF NUTRITION

Alongside medical interventions, adopting a healthy lifestyle plays a crucial role in the success of IVF treatments. A well-balanced diet is vital, as it provides essential nutrients, minerals, and vitamins necessary for optimal egg and sperm production, which increases the chances of a successful outcome. Moreover, consuming nutrient-rich foods nourishes the eggs and uterus, promotes timely ovulation, supports the womb, and slows egg degeneration. By aiding egg health and maintaining balanced reproductive hormones, such a diet helps protect cells and boosts the likelihood of pregnancy.

HOPE FOR MANY, NOT ALL

IVF is a common treatment for infertility, particularly for those over 40. This procedure is also a viable option for those facing conditions such as diminished egg reserve, ovulation disorders, endometriosis, fallopian tube damage or blockages, uterine fibroids, or certain genetic disorders. Additionally, it can benefit individuals who have undergone past surgeries to prevent pregnancy or those affected by male infertility factors like low sperm count or quality. However, while IVF offers a significant pathway to

overcoming infertility, it is essential to note that success rates can vary depending on factors such as age, health, and the cause of infertility. It is not recommended for people with large fibroid tumours, severe ovarian dysfunction, or morbid obesity.

EXPANDING HORIZONS OF FERTILITY

Beyond traditional IVF, advances in fertility preservation and genetic testing offer couples even more options for family planning. Techniques such as egg, sperm, and embryo freezing allow individuals to delay parenthood if they are not yet ready to start a family. Additionally, for those undergoing treatments that may impact fertility, such as cancer therapy, options like ovarian and testicular tissue cryopreservation are proving invaluable.

"Ovarian tissue cryopreservation and transplantation are vital fertility preservation methods for adult cancer patients who need immediate chemotherapy,” explains Dr. Wael Ismail Madkour, a Fertility & Reproductive Endocrinology (IVF) Consultant at HealthPlus Fertility Center. He adds that ovarian tissue freezing is currently the only method available to preserve fertility in prepubertal cancer patients, giving cancer survivors the future opportunity for motherhood.

Meanwhile, advancements in genetic screening have significantly improved IVF success rates. By identifying and selecting embryos without genetic abnormalities, doctors can increase the likelihood of a healthy pregnancy. Dr. Najjari highlights that transferring a single genetically normal embryo can lead to

a success rate of up to 70%, while transferring two embryos may increase this rate to 80%. However, she cautions that transferring multiple embryos raises the risk of multiple pregnancies, which can be more complex and is generally not recommended.

DISPELLING THE MYTHS

Despite the growing acceptance of IVF, several misconceptions persist. Many still perceive infertility as primarily a women’s issue, though WHO reports male factor infertility, which can be caused by disruption of testicular or ejaculatory function, as well as by hormonal and genetic disorders contributing to nearly half of all cases. Additionally, many people believe IVF guarantees success, but while it significantly improves the chances of pregnancy, it does not work for everyone. IVF can also be costly, but there are various financial support systems available to help couples manage the expense.

NAVIGATING THE ETHICAL MAZE

As IVF continues to gain popularity globally, the United Arab Emirates has taken steps to regulate this growing industry with significant policy updates. In June 2024, the UAE updated Federal Law No. (7) of 2019, which concerns medically assisted reproduction, to permit unmarried nonMuslim couples to undergo IVF. This amendment also removed the previous restriction that prohibited the use of surrogate mothers, and the country has relaxed its laws on embryo freezing, which was once banned in the Gulf nation. Nevertheless, the law still mandates that only a

husband can be the sperm donor, and only the wife can provide the egg for IVF procedures. Meanwhile, the landscape surrounding reproductive rights remains contentious in the United States, where the issue is increasingly tied to the debate over abortion. In February 2024, the Alabama Supreme Court ruled that frozen embryos are considered children, which meant that anyone who accidentally destroys them could be held liable. This has placed the future of IVF treatments in Alabama in question; several healthcare providers in the state have suspended their IVF services, while some antiabortion advocates support the decision, arguing that embryos should be granted more robust legal safeguards.

DESIGNING THE FUTURE OF FAMILY

Despite these legal challenges, the field of fertility treatment is evolving rapidly, with innovative solutions offering hope to those struggling to conceive. Emerging technologies, including IVF-on-a-chip and digital microfluidic processing, promise to streamline traditional IVF methods, making them more efficient, effective, and affordable. Additionally, developments in bioprosthetic ovaries could restore reproductive function, providing new possibilities for women who have lost their natural fertility. For a sustainable future, it is crucial to address ethical considerations, enhance accessibility, and create supportive regulatory frameworks surrounding IVF to enhance the benefits for individuals and society. HCMEA

HEALTHCARE AT THE DOORSTEP:

How Benacare’s

“hospital at home” is redefining care for Kenya’s chronically ill

By VINCENT MORANGA

With a population exceeding 50 million, access to healthcare remains a critical issue in Kenya, especially for chronically ill patients in middle—to low-income neighbourhoods. For these individuals, hospital visits can be prohibitively expensive, time-consuming, and stressful, particularly when long-term care is needed.

Bena Care, a social enterprise, is working to bridge this gap by offering affordable, high-quality, home-based nursing and inhome therapy like critical care, general nursing care, physiotherapy, caregiving and occupational therapy as well as lease of homecare equipment like hospital beds etc.

BENACARE’S INNOVATIVE MODEL

Bena Care, founded in 2017, was created with a clear mission: to

make healthcare more accessible and alleviate chronically ill patients’ challenges. The inspiration behind this innovative company came from founder and CEO Naomi Monari, who recognized the financial and emotional toll that hospital-based care places on patients and their families.

As a student nurse, Monari often witnessed how chronic illness weighed on patients and their families. She saw how people remained in hospitals, not because they needed critical interventions, but because they required routine or supportive care that wasn’t available at home. This gap in the healthcare system struck her deeply, sparking the question, what if these patients could receive the care they need at home?

“Imagine having a loved one who needs daily support just to get through the basics like eating or bathing,” Monari says. “These are people who don’t necessarily need

to be in a hospital setting, but they have no other options.” From this realization, Bena Care was born—a concept Monari calls a “hospital at home.”

Monari and her team at Bena Care bring healthcare to patients’ doorsteps, allowing them to stay close to family and avoid the impersonal environment of hospital when the care needed can be given at home.

BUILDING A NETWORK OF COMMUNITY CARE

The uniqueness of Bena Care’s approach lies in its people. Instead of relying on traditional in-hospital teams, Monari has established a network of local healthcare workers, including nurses, physiotherapists, and caregivers who are well-equipped to provide comprehensive homebased care. This “Uber of healthcare,” as Monari calls it, ensures that patients receive care from professionals in their communities.

Bena Care matches healthcare workers to patients based on their location, which reduces travel time and cost. “If a patient is in Village A, we connect them with a nurse from Village A or nearby,” Monari shares. “This makes care not only accessible but also affordable, because we cut down on travel and logistical expenses.”

The reach of Bena Care’s network is significant. Since launching, they have served over 16,000 patients and provided steady, dignified work to more than 3,000 healthcare professionals. By offering flexible, consultant-like roles, Bena Care has created a model that serves both patients and the healthcare workforce. “We empower our nurses and caregivers to work with us on a project basis, like drivers on a ride-sharing app. They get paid for each assignment, allowing them to balance work with other personal commitments,” Monari explains.

MAKING HOME HEALTHCARE AFFORDABLE

For families dealing with chronic illness, the cost of equipment—such as hospital beds, oxygen concentrators, or wheelchairs—can be overwhelming. To address this, Bena Care offers an affordable equipment leasing program that provides access to necessary medical devices without requiring families to make a large, upfront investment. “We have found a way to relieve families of the financial pressure that comes with managing long-term illnesses at home,” says Monari. “By leasing out equipment, we allow them to focus on what really matters— caring for their loved ones.”

SINCE LAUNCHING, THEY HAVE SERVED OVER 16,000 PATIENTS AND PROVIDED STEADY, DIGNIFIED WORK TO MORE THAN 3,000 HEALTHCARE PROFESSIONALS.

This approach has made home-based care financially accessible for low-income families, many of whom struggle to pay for extended hospital stays. “Instead of buying an oxygen concentrator for a one-time high cost, families can lease it monthly,” Monari explains. “It’s the difference between affording care and not.”

Bena Care’s commitment to affordability extends to the training and resources they offer their healthcare workers, ensuring that every nurse or caregiver who joins the network is prepared to deliver top-tier care. “We want our team to feel supported and prepared,” Monari says. “It’s not just about building a business; it’s

A CAREGIVER ATTENDING TO AN ELDERLY PATIENT DURING HOMECARE SESSION

about building a community of compassionate caregivers who treat every patient with respect and dignity.”

A JOURNEY MARKED BY CHALLENGES AND TRIUMPHS

Bena Care’s success has not gone unnoticed. They’ve earned several awards, including the prestigious Global Citizen Waislitz Award in New York, which Monari describes as a turning point for the company. “Winning that award validated our work on a global scale,” she shares. “It was proof that our efforts to disrupt traditional healthcare systems were making an impact.” Bena Care has also been recognized locally, earning accolades such as the Zuri Award for Digital Resilience for using technology to manage their healthcare network.

LOOKING AHEAD: A VISION FOR HEALTHCARE IN KENYA

Monari’s vision remains clear as Bena Care grows: a healthcare system where access is not determined by geography or income. “Our goal is to ensure that every patient, regardless of their financial situation or location, has access to dignified and compassionate care,” she says. With plans to expand the mobile dialysis units to more regions and continue building their network of local caregivers, Bena Care is on a path to making this vision a reality.

As the demand for home-based care grows, Bena Care is investing in expanding its services to offer mobile dialysis and exploring opportunities to integrate Artificial Intelligence (AI) into its offerings. Through its collaboration with Boehringer Ingelheim and Muranga County, Bena Care is set to roll out mobile dialysis stations in the coming years, bringing essential healthcare services directly to patients’ communities.

While AI integration remains a future goal, Bena Care is already harnessing technology to enhance its digital healthcare capabilities. The company has digitised its scheduling system

to streamline nurse dispatch to patient locations. This new platform matches nurses with specific patient needs to optimize the scheduling process and allow flexibility for nurses to work remotely whenever possible. Additionally, Bena Care’s collaboration with teleconsultation providers will enable patients to easily consult with doctors online, further supporting its vision of accessible, tech-enabled healthcare.

As Bena Care continues to expand, Monari reflects on th journey. “This work is about more than healthcare,” she says with conviction. “It’s about community, compassion, and creating a model of care that can be sustained for generations to come. We’re just getting started.”

ADVERTISE IN HEALTHCARE AFRICA MAGAZINE & WEBSITE?

• Reach the healthcare, pharmaceutical and biotech industry in Africa & Middle East using one publication and website

• The first magazine of its kind in the region that is also available in a digital format, providing our advertisers with a regional and worldwide audience

• The magazine and website are read by key decision makers with direct responsibilities for purchase of new technologies, products and services across Africa, Middle East and globally.

• HealthCareMEA.com is the best read and visited healthcare, pharmaceuticals and biotech news website in Africa and the Middle East.

BREAKING THE CHAINS: Bridging the Gap in Sickle Cell Disease Management Across Africa

By VINCENT MORANGA

In a world increasingly focused on combating cancer, sickle cell disease (SCD) has emerged as a significant risk factor for haematological malignancies. SCD and its variants, such as Sickle Cell Anemia (SS) and Sickle Beta-Zero Thalassemia, are characterized by a transformation in the shape of red blood cells. Instead of their normal, smooth, doughnut-like structure, these red blood cells take on a crescent or half-moon shape.

Because of this abnormal shape, these sickle cells become rigid and sticky, which can impede blood flow. This impairment hinders the body’s ability to produce sufficient haemoglobin, the protein responsible for transporting oxygen. The absence of adequate haemoglobin can lead to organ oxygen deprivation. Individuals with SCD often experience a range of debilitating symptoms, from mild to severe pain, swelling of the hands and feet, recurrent infections, delayed growth, vision impairments, and, in severe cases, acute chest syndrome.

Despite the availability of low-cost preventative therapies, inadequate resource allocation has hindered progress made in reducing the burden of SCD as compared to other public health

initiatives in Africa. This article will highlight the prevalence, management options, and recent breakthroughs in SCD treatment in Africa, which are all essential for enhancing the quality of life for affected individuals.

A CONTINENT IN CRISIS

With sickle cell disease (SCD) being considered more prevalent in Africa, the World Health Organization (WHO) estimates that as of 2022, approximately 66% of the 120 million global cases originated in Africa. Nigeria has the highest disease burden in Africa and the globe, with over 150,000 births per year. The Federal Ministry of Health in Nigeria further estimates that about 50-90% of these individuals die before the age of five, with approximately 24% of Nigerians possessing the sickle cell trait.

Apart from Nigeria, other nations, such as Kenya, also bear this burden, with roughly 14,000 infants born with sickle cell disease annually. The Kenyan Ministry of Health data further indicates that this disease burden is consistent with malaria endemic patterns, with high prevalence in the lake region,

western and coastal regions, and widespread prevalence in urban and commercialized areas due to migratory trends.

In 2019, the WHO reported that 38,403 people in Africa died from sickle cell disease, a 26% increase from 2000. This increased burden was caused by insufficient investment in disease-fighting activities, leaving many regional public health facilities needing help to provide the necessary preventive, early detection, and care services. Additionally, a lack of competent professionals and inadequate services at lowerlevel health facilities limit an effective response to the disease.

In recognition of this crisis, Dr Matshidiso Moeti, WHO Regional Director for Africa, has been keen on calling for better resource allocation. "Most African countries do not have the necessary resources to provide comprehensive care for people with sickle cell disease despite the availability of proven cost-effective interventions for prevention, early diagnosis, and management of this condition," she said.

A MULTI-PRONGED APPROACH

Given that there is no definitive treatment for SCD, standard medications have been used to help minimize disease-related adverse effects. These drugs include hydroxyurea, which reduces the frequency of sickle cell crises; voxelotor (Oxbryta), which diminishes sickling while increasing the number of red blood cells; crizanlizumab (Adakveo), which makes red blood cells more slippery and reduces pain crises; and L-glutamine, which is taken orally to relieve pain.

Although bone marrow transplant is currently the only known cure for SCD, it is considered

complex and risky and only available to select people. Scientists have also developed novel methods, such as gene therapy, which is regarded as a potential cure for sickle cell anaemia. Gene therapy involves replacing a defective gene with a healthy one, which allows the body to create normal red blood cells.

According to Nicole Verdun, M.D., director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research, “Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited.”

As of December 2023, the FDA authorized Casgevy and Lyfgenia as emerging gene therapies, a significant step forward in SCD treatment as a potential alternative therapy for patients aged 12 and above. Casgevy uses CRISPR gene-editing technology, a revolutionary technique that allows for precise gene editing to increase foetal haemoglobin production, improve oxygen supply, and prevent sickling. In contrast, Lyfgenia inserts a gene into the patient's blood stem cells, resulting in normal haemoglobin.

THE EVOLVING LANDSCAPE OF SICKLE CELL DISEASE TREATMENTS

As hydroxyurea and other drugs become more widely available worldwide, a significant unmet need for innovative treatments for sickle cell disease (SCD) remains. Sickle cell anaemia, which has long been categorized as an orphan disease, has prompted both the U.S. FDA and the European Medicines Agency (EMA) to incentivize pharmaceutical companies.

GLOBAL SICKLE CELL DISEASE CASES AS OF 2022

These incentives include shorter approval periods and lower development costs for innovative therapies, encouraging greater investment in SCD treatments. Major pharmaceutical corporations have often been promised extended exclusivity periods, free from generic competition.

With SCD becoming increasingly prevalent in regions like Africa, there is a growing opportunity to attract investments in these emerging markets. One major beneficiary of these incentives is Novartis. The company has now developed child-friendly formulations of hydroxyurea to facilitate easier medicine administration for children who struggle to swallow capsules. Additionally, Novartis is conducting two clinical trials in Ghana and Kenya for its next-generation SCD medication. If approved, these trials would represent the first use of biological therapy, rather than a vaccine, in multicenter clinical studies in Sub-Saharan Africa, excluding South Africa.

Pfizer, a Novartis competitor, also holds a substantial market share. In August 2022, Pfizer spent US$5.4 billion on Global Blood Therapeutics, the creator of Oxybryta, to extend its SCD portfolio. This acquisition expanded Pfizer’s rare haematology portfolio by introducing two new pipeline assets, GBT601 and inclacumab, both of which target SCD. Similarly, in September 2022, Danish pharmaceutical titan Novo Nordisk paid US$1.1 billion for Forma Therapeutics to extend its blood disorder medicine portfolio.

Unlike traditional SCD therapies, novel gene treatments are gaining traction in the SCD treatment landscape. Casgevy, developed collaboratively by Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia by Bluebird Bio, are emerging as promising alternatives to bone marrow transplants. Dr Cece Calhoun, MD, MBA, a haematologist-oncologist at Yale Medicine, notes that these therapies represent a significant advancement. Additionally, Editas Medicine has entered this competitive arena with EDIT-301, an experimental geneediting treatment for SCD that could rival Casgevy.

HARNESSING AFRICA’S BOTANICAL POWER

Conventional medications, such as hydroxyurea, have long been the primary treatment for sickle cell disease (SCD). However, traditional African treatments present considerably

EDITAS MEDICINE HAS ENTERED THIS COMPETITIVE ARENA WITH EDIT-301, AN EXPERIMENTAL GENE-EDITING TREATMENT FOR SICKLE CELL DISEASE THAT COULD RIVAL CASGEVY.

more advanced health and wellness concepts than many biomedical scientists might expect. In regions like Nigeria, doctors have been using Fagara (Fagara zanthoxyloides) to alleviate the agonizing symptoms of sickle cell anaemia. This plant possesses unique properties that inhibit the stickiness of platelets and blood cells, offering an alternative approach to managing the disease.

Nigeria has also developed Niprisan, a remarkable drug formulated by the Nigerian National Institute for Pharmaceutical Research and Development (NIPRD). This phytochemical blend is derived from four indigenous plants: Piper guineenses seeds, Pterocarpus osun stems, Eugenia caryophylum fruit, and Sorghum bicolor leaves. While Niprisan is not a cure for sickle cell anaemia, it has proven effective in significantly reducing the frequency of painful crises in patients without causing toxicity or severe adverse effects.

STRENGTHENING AFRICA’S FIGHT AGAINST SCD

With Africa disproportionately affected by Sickle Cell Disease (SCD), the use of technologies such as newborn screening (NBS) remains underutilized. However, Africa could benefit from lessons learned in developed nations, where healthcare systems have successfully integrated NBS programs into antenatal care. This early detection approach not only improves data collection and analysis but also enhances accurate monitoring of disease impacts and outcomes. Furthermore, it promotes scientific research, training, and collaboration, all of which are crucial in shaping a comprehensive SCD treatment plan.

In June 2024, WHO Africa took another significant step by issuing major recommendations to intensify Africa’s fight against SCD. These recommendations, captured in the ‘Guidance Framework for Sickle Cell Disease Management’ and the ‘Harmonised Guide for Sickle Cell Disease Management,’ offer precise, actionable solutions. They aim to help countries improve the quality of care, expand access to treatments, and enhance overall health outcomes in the fight against SCD across the region.

GERMANY — Siemens Healthineers has been awarded the CE Mark for two innovative features in its PET Cortical Analysis software: centroid scoring and Tau PET quantification.

These additions enhance the syngo.PET Cortical Analysis software, expanding the company’s comprehensive portfolio for Alzheimer’s disease detection, diagnosis, monitoring, and management.

The advanced software utilizes positron emission tomography (PET) technology to measure protein deposits in the brain associated with Alzheimer’s disease, the most common form of dementia.

Centroid scoring establishes a standardized method for measuring amyloid plaques in PET images.

This feature supports three commercially available beta-amyloid

Anryton unveils Layer One Network and DNA NFT technology Siemens Healthineers Receives CE Mark for Advanced PET Cortical Analysis Features

UAE — Anryton, a leader in data security and flow solutions, has introduced its innovative Layer One network and DNA NFT technology to revolutionise data storage, privacy, and exchange across multiple industries.

Anryton’s cutting-edge DNA NFT technology leverages Variant Call Format (VCF) files to create secure digital wallets, significantly enhancing

PET radiopharmaceuticals, which are crucial for accurate Alzheimer’s diagnosis.

In addition, Siemens Healthineers’ Tau PET quantification simplifies the evaluation and quantification of tau protein tangles in the brain, using PET images obtained with the radiopharmaceutical flortaucipir.

The Tau PET method incorporates Braak staging, a six-stage model that illustrates the progression of tau disease in the brain.

Tau PET has been widely used in recent clinical trials targeting amyloid, aiding in patient classification, drug management, and treatment response assessment.

According to the World Health Organization (WHO), more than 55 million people worldwide live with dementia, with 60% of those affected

residing in low- and middle-income countries.

Dementia is the seventh leading cause of death globally and plays a significant role in the dependency and disability of the elderly.

In 2019, an estimated US$1.3 trillion was spent on dementia, with informal carers bearing about half of the costs.

data privacy and storage capabilities.

This new approach allows for greater protection and control over sensitive data, particularly in industries where security is paramount.

The Layer One network, designed to be scalable, secure, and highly efficient, is a versatile platform that supports a wide range of applications.

Its capabilities promise to transform industries such as healthcare, legal, supply chain, and data management, offering robust security and seamless data exchange.

By integrating VCF files into NFTs, Anryton is pioneering new applications in data security, particularly in healthcare, where safeguarding privacy is critical.

This unique combination ensures that data exchanges occur only between authorised parties while individuals control their sensitive information.

With the power of blockchain technology, Anryton’s Layer One network and DNA NFT technology are poised to streamline processes, enhance data integrity, and drive innovation across sectors, offering unparalleled security and efficiency.

ANRYTON’S CUTTING-EDGE DNA

NFT TECHNOLOGY LEVERAGES VARIANT CALL FORMAT (VCF) FILES TO CREATE SECURE DIGITAL WALLETS.

Philips and icometrix partner to revolutionize MRI Brain Scans with AI

EUROPE — Royal Philips, a global leader in health technology, has partnered with icometrix, a Belgian company specialising in AI-powered diagnostic solutions, to create an innovative solution for MRI brain scans.

This collaboration is designed to improve the diagnosis and monitoring of neurological diseases such as Alzheimer’s disease and Multiple Sclerosis (MS).

The new solution, showcased at the RSNA 2024 conference, integrates icometrix’s advanced software with Philips’ latest BlueSeal MR scanners.

This powerful combination enhances diagnostic accuracy and streamlines the entire process, from image acquisition to reporting, using AI-driven Smart Reading capabilities.

One key benefit of this partnership is its impact on Alzheimer’s diagnosis and monitoring.

The icobrain dm software developed by isometric enables healthcare professionals to accurately differentiate between various types of dementia.

Additionally, the FDA-cleared icobrain ARIA software allows for precise identification and assessment of amyloidrelated imaging abnormalities (ARIA), which can occur as a side effect of anti-amyloid treatments.

By closely monitoring ARIA throughout treatment, neurologists can make informed decisions that minimize risks while maximizing therapeutic benefits.

Regarding Multiple Sclerosis management, the BlueSeal MR scanners are equipped with AI-enhanced SmartExam planning and SmartSpeed protocols that facilitate rapid acquisition of specialized MRI sequences, including FLAIR imaging.

The icobrain MS software further enhances this process by enabling precise detection and tracking of white matter lesions around veins—a key indicator of MS.

This integrated solution allows for longitudinal comparisons of MRI scans, providing valuable insights that can guide treatment strategies.

Pfizer introduces digital platform to streamline healthcare access

USA — Pfizer Inc. has launched PfizerForAll, a user-friendly digital platform designed to improve access to healthcare and manage health and wellness for people across the United States.

The introduction of PfizerForAll comes after Eli Lilly launched a similar program, LillyDirect, which allows patients to obtain pharmaceuticals directly from the corporation, including its weight-loss prescription Zepbound.

Unlike LillyDirect, PfizerForAll will allow patients to continue using their current insurance and pharmacy programs while benefiting from new services provided by UpScriptHealth, Alto Pharmacy, and Instacart.

PfizerForAll seeks to save time and effort for individuals and families taking crucial health actions, including receiving care, filling prescriptions, and uncovering possible savings on Pfizer pharmaceuticals by unifying essential resources and services into one platform.

The platform also provides prescription drugs, over-thecounter treatments, and diagnostic testing for home delivery or pickup at a recommended local pharmacy.

In addition, PfizerForAll facilitates appointment scheduling for adult COVID-19, flu, RSV, and pneumococcal pneumonia vaccinations.

Users can check their eligibility for these vaccines, find availability in their local area, and book an appointment at a preferred retail pharmacy.

The platform also streamlines the payment process for Pfizer medications by consolidating savings and support solutions in one place.

It makes it easier for patients with commercial insurance to find co-pay cards and for eligible patients to access Pfizer’s affordability programs and patient support services.

Pfizer plans to continue expanding and developing PfizerForAll to enhance the healthcare experience for people in the U.S., potentially addressing a broader range of needs and conditions.

Africa CDC approves Morocco’s homegrown Mpox test

MOROCCO — The Africa Centres for Disease Control and Prevention (Africa CDC) has approved Morocco’s first locally manufactured Real-Time PCR test for mpox, the UM6P-MAScIR MPOX qPCR 1.0.

This significant development was announced on November 12, 2024, as part of Africa CDC’s ongoing efforts to enhance diagnostic capabilities across the continent.

Developed by Moldiag, a Moroccan diagnostic company, the test has been included in the latest recommended list of mpox diagnostic tests by the Africa CDC’s Diagnostic Advisory Committee (DAC).

The DAC plays a crucial role in evaluating and validating diagnostic technologies throughout Africa, ensuring that only the most reliable tools are recommended for national testing strategies.

The UM6P-MAScIR test was approved after a rigorous evaluation process aligned with World Health Organization (WHO) standards.

The DAC confirmed that the test met all essential criteria based on independent evaluations conducted by the National Institute for Biomedical Research (INRB) in the Democratic Republic of Congo.

This endorsement is viewed as a major milestone in strengthening Africa’s self-sufficiency in public health. It aligns with the African Union’s broader goal of enhancing local production of medical diagnostics and reducing reliance on imports.

The timing of this approval is critical, as it comes amid a declared public health emergency due to mpox, which has resulted in over 59,000 cases and 1,164 deaths reported across 20 African

countries this year.

The Africa CDC has actively supported members through its comprehensive continental plan by distributing PCR and genome sequencing test kits, GeneXpert cartridges, and molecular testing.

Dr. Jean Kaseya, Director General of Africa CDC, expressed optimism that this achievement could inspire local manufacturers to innovate further in developing diagnostic tools and other epidemic-related products.

THE UM6P-MASCIR TEST WAS APPROVED AFTER A RIGOROUS EVALUATION PROCESS ALIGNED WITH WORLD HEALTH ORGANIZATION (WHO) STANDARDS.

Ypsomed to supply pens for Novo Nordisk’s CagriSema

SWITZERLAND—Swiss medical technology company Ypsomed will supply injection pens for Novo Nordisk’s CagriSema, the Danish drugmaker’s next-generation obesity drug. This follows an agreement of September 2023 in which the company aims to support Novo Nordisk’s long-term

commercial production plans for CagriSema, which is currently in latestage clinical trials.

CagriSema is expected to be a more effective successor to Wegovy, Novo’s popular obesity treatment. It aims to help patients lose an average of 25% of their body weight within a year, significantly improving over Wegovy’s 15% average weight loss.

The success of CagriSema is crucial for Novo Nordisk’s position in the competitive obesity treatment market, especially as it faces increasing competition from Eli Lilly’s Mounjaro. The Phase III trial results for CagriSema, expected by the end of this year, could be a game-changer for the company’s future in the obesity treatment sector.

In addition to the CagriSema

deal, Ypsomed has also committed to expanding its manufacturing capacity to produce autoinjectors for Novo’s “second-generation GLP-1” drugs, which are still in clinical trials.

Although Novo Nordisk is developing experimental oral obesity pills, the company expects injections to remain the dominant delivery method for its weight-loss treatments through the end of this decade.

Ypsomed, the world’s second-largest supplier of autoinjectors by sales to the pharmaceutical industry, has also secured deals with 31 companies related to GLP-1 drugs. The company’s stock has risen by approximately 18% this year, reflecting the growing demand for its products and services in the expanding obesity treatment market.

Russia pioneers AI in Healthcare Education Olympus elevates ENT Diagnostics with VISERA S

JAPAN — Olympus Corporation, a global leader in medical technology, has introduced the VISERA S, an advanced allin-one imaging platform designed to enhance diagnostic capabilities for Ear, Nose, and Throat (ENT) specialists.

This state-of-the-art platform, the VISERA S, uniquely integrates stroboscopy, narrow-band imaging (NBI) technology, and high-definition (HD) video, providing a comprehensive tool to enhance the detection, characterisation, and treatment of ENT conditions.

VISERA S leverages Olympus’ NBI technology, which enhances contrast and visibility, particularly for vascular structures and mucosa.

With these advancements, the platform significantly boosts clinicians’ ability to perform detailed assessments, streamlining workflows and ensuring higher precision in diagnosing ENT diseases.

A key highlight of the VISERA S is its ability to combine multiple functionalities previously spread across separate devices into one unified system.

Clinicians can seamlessly switch between white light, NBI, and stroboscopy modes with the push of a button on the VISERA S, improving operational efficiency and ease of use during procedures.

Additionally, VISERA S offers enhanced compatibility with a range of Olympus equipment, including scopes, camera heads, and monitors, while also expanding its image and video storage capabilities.

Unlike previous models that were limited to still image storage, the new platform can record high-quality video, ensuring comprehensive procedural documentation and better reporting.

The VISERA S’s video system center integrates multiple light sources, eliminating the need for separate components and simplifying the clinician’s setup.

This innovative platform will be available in Europe, select parts of Asia, and Oceania starting in September 2024, with plans to expand to other regions as regulatory approvals are obtained.

RUSSIA — The Moscow Healthcare Department’s Centre for Diagnostics and Telemedicine, in conjunction with MIREARussian Technological University, has pioneered the integration of artificial intelligence into Russian healthcare education.

Building on the success of AI applications in medical imaging analysis, as announced by the Center for Diagnostics and Telemedicine in September, the university has introduced a bachelor’s degree in “Technologies and Systems of Artificial Intelligence in Healthcare” and a retraining program focused on “Development and Testing of Artificial Intelligence Services in Healthcare.”

The collaboration has already yielded tangible results, such as the successful placement of students from the Master’s program in “Intelligent Data Analysis.”

The unique bachelor’s and retraining programs, unmatched in Russia’s educational landscape, offer students handson experience with big data management, AI tool quality assessment, and developing AI-driven software solutions.

This program leverages the expertise of the Center for Diagnostics and Telemedicine, a leading institution in AI research and application in healthcare

Additionally, technology partners like the Third Opinion Platform and Yandex Cloud play a crucial role, providing students with opportunities to engage with industry experts, participate in paid internships, and work on real-world AI projects.

This collaboration aligns with MIREA’s involvement in the Priority 2030 Strategic Academic Leadership Program, which fosters partnerships with industrial leaders.

This initiative further solidifies Russia’s position in merging AI and healthcare education by building upon their past success, including the advanced training program in Aspects of Development and Testing of Artificial Intelligence Technologies in Healthcare.